

CURRICULUM VITAE - K. Riesbeck

Contact details

Name: Kristian Riesbeck
Born: 30th January, 1962 (Swedish ID: 19620130)
Marital status: married, 2 children (ages 24 and 26 years)
Institute: Clinical Microbiology, Dept. of Translational Medicine, Lund University, Jan Waldenströms gata 59, SE-21428 Malmö, Sweden
Tel: +46 (0)40 338494, +46(0)73 0377433
e-mail/ web: kristian.riesbeck@med.lu.se,
<http://research.med.lu.se/kristian-riesbeck>



Education/ professional record

1987-94; Graduate student, Dept. of Medical Microbiol., University Hospital, Malmö
1987-88; Laboratory physician, Dept. of Clinical Microbiology, Malmö
1989; **MD**, Lund University
1990-92; Clinical practice (totally 21 months, internship), Malmö
1992; Licence to practice as a physician in Sweden
1994 ; **PhD** (Effects of fluoroquinolones on the immune system), Medical Microbiology, Lund University
1994-1996; Senior Postdoctoral Research Officer, Dept. of Immunology, Royal Postgraduate Medical School (RPMS), Hammersmith Hospital, London, UK
1996-1998; Head, Cell and Molecular Biology section, Pharmacia & Upjohn, Lund
1998; **Associate Professor**, Lund University
1999-2007; Physician, Dept. of Infectious Diseases, Skåne University Hospital
1999; Specialist in **Clinical Bacteriology**
2006; Specialist in **Clinical Virology**
2008-2011; Head, Department of Laboratory Medicine Malmö, Lund University
2012-2013; Deputy Dean, Medical Faculty, Lund University

Current positions

from 2005; **Senior Consultant**, Clinical Microbiology, Laboratory Medicine Skåne, Lund
from 2008; **Professor** in Clinical Bacteriology (externally advertised position), Lund University

Awards and distinctions

1999; The Domaqk Scholarship, Swedish Society of Infectious Diseases
2002; Successful Young Scientist Award, Malmö University Hospital
2002; Best lecture award, Swedish Soc. of Medicine, Clinical Microbiology
2004; Younger scientists ALF at the County of Skåne, 3rd period; 2005-2007 (3 received it)
2006; Wallenberg Foundation, 50 % Research for Clinicians 2008-2010 (only 6 in Sweden)
2011; Best lecture award, Swedish Soc. of Medicine, Clinical Microbiology

Commissions of trust and Review assignments

- Member of the Scientific Advisory Board for The International Leibniz Research School for Microbial and Biomolecular Interactions (ILRS), Jena, Germany.
<http://www.ilrs.de/advisory-board.html>
- Treasurer of "Malmö Allmänna Sjukhus Stiftelse för bekämpande av Cancer"
www.mascancerstiftelse.se
- Member of Skåne University Hospital (SUS) foundation priority committee´.
- Member of the Steering Board of the National Infection Biology Network (www.ndpia.se), Umeå, Sweden.

- Member of the Royal Physiographical Society in Lund, and in the priority committee of Forssman's Foundation. <https://www.fysiografen.se/en/>
- Referee for Nature Communications, Nature, Journal of Infectious Diseases, Journal of Immunology, Infection and Immunity, PLoS Pathogens, Molecular Microbiology, Nature communications, Transplantation, Journal of Leukocyte Biology, European J. of Clinical Investigation, The Journal of Chemotherapy (Editorial Board), FEMS Microbiology letter, Microbes and Infection, Antimicrobial Agents and Chemotherapy, Journal of Antimicrobial Chemotherapy, Acta Pathologica Microbiologica Scandinavica (APMIS), , PLoS One, Scandinavian Journal of Infectious Diseases, and The Lancet Infectious Diseases.
- Reviewer for "Svenska Läkaresällskapets fonder (AFA försäkring)", Irish Medical Council, South African Medical Council, British Society for Antimicrobial Chemotherapy, Medical Research Council (UK), Icelandic Medical Research Council and Finnish Medical Research Council (2019).
- Scientific consultant for Astra-Zeneca, Lund (mitigation of new candidate drugs; 1st time in man), 2007-2009.
- Scientific advisor for Truly Translational, Lund 2009-present.
- Medical advisor for MSD Vaccines, Philadelphia 2016.
- Scientific consultant (advisory board) for GlaxoSmithKline, 2008-2013 and 2019.
- Swedish Medical Agency: Expert board, Rhinosinuitis, 2019.
- Wallenberg Clinical Scholar 2019 (SEK 15.000.000)
<https://kaw.wallenberg.org/en/wallenberg-clinical-scholars-2019>
- Reviewer for Independent Research Fund Denmark, Review board, 2020 and 2021.
- Member in the Scientific Advisory board (SAB) for National Graduate School in Infection Biology and Antimicrobials in Norway, 2017-2023
- Member in "Folkhälsomyndighetens referensgrupp för Nationella vaccinfrågor" (Reference group for the National vaccine programme at the Swedish CDC) 2015-2020.
- Scientific consultant (advisory board) for Pfizer, 2023.

PhD students, with applicant as *main* supervisor at Lund University, previous (*n*=20) and current (*n*=7)

- | | |
|--|--|
| 1. Irin Lazou Ahrén (MSc) graduated 2002-10 | 14. Magnus Paulsson (MD), 2017-06 |
| 2. Andrea Möllenkvist (MSc), 2005-10 | 15. Sepideh Lamei (MSc), 2018-05 |
| 3. Theresé Nordström (MSc), 2005-04 | 16. Viktor Månsson (MD), 2019-02 |
| 4. Martin Samuelsson (MSc), 2006-12 | 17. Nils Littorin (MD), 2019-06 |
| 5. Thuan Tong Tan (MD), 2007-01 | 18. Fabian Uddén (MD), 2022-11 |
| 6. Teresia Hallström (MSc), 2007-05 | 19. John Thegerström (MD), 2023-11 |
| 7. Johan Jendholm (MSc), 2008-11 | 20. Oskar Thofte (MD), 2025-06 |
| 8. Elena Ronander (MSc), 2009-01 | 21. Karin Hansén (MD), from 2016- |
| 9. Taras Manolov (MSc), 2009-05 | 22. Elisabeth Rünöw (MD), from 2016- |
| 10. Fredrik Resman (MD), 2012-09 | 23. Kirsti Lindström (MSc, nurse), from 2017- |
| 11. Viveka Schaar (MSc), 2013-09 | 24. Linda Yamba-Yamba (MD) from 2021- |
| 12. Farshid Jalalvand (MSc), 2015-01 | 25. Sandra Jonsson (fil. mag.), from 2021- |
| 13. Tamim Al-Jubair (MSc), 2016-06 | 26. Thomas Sahlström (MD), from 2023 |
| | 27. Valdemar Öhnström (MSc), from 2025- |

Post-docs, previous (*n*=20) and current postdocs (*n*=5)

Anthony Myoumbwe (Japan) 2001-2003; Teresia Hallström (Sweden) 2007; Maria L. Perez Vidakovics (Argentina) 2008-2010; Theresé Nordström (Sweden) 2009; Lin Tan (UK) 2010; Can Ünal (Germany) 2009-2011; Kalpana Singh (Germany) 2009-2011; Claudia Rodas (Sweden/ Bolivia) 2011-2012; Chrystelle Derache (France) 2011-2012; Emma Nordahl (Sweden) 2011; Christophe Fleury (France) 2011-2013; Florence Deknuydt (France) 2011-2013; Tamara Richter (Ireland) 2014; Birendra Singh (India/Germany) 2008-2015; Oindrilla Mukherjee (India/Germany) 2013-2014; Alfonso Felipe-Lopez (Mexico/Germany) 2014-2015; Farshid Jalalvand (Sweden) 2015; Corinna Richter (Germany/ New Zealand) 2014-2016; Ben Duell (Australia) 2014-2016; Petra Halang (Germany) 2014-2016; Yu-Ching Su (Malaysia) 2009-present; Tamim Al-Jubair (India/ Sweden) 2016; Guillaume Manat 2017-2019; Sujinna Lekmechai 2017-2019; Farshid Jalalvand 2019-2022; Mahendar Kadari 2019-2021, Megan Straw 2020-2024, Martina Janousková 2020-, Onur Bulut 2022-2023, Bruno Alejandro Steimbruch 2022-2024, Jale Boral 2024-, Nirmal G.Rajindran 2025-, Abhijeet G. Lokras 2025-, Hanna Isakova 2025-.

PUBLICATIONS

1. Original articles (n=238)

1. Bredberg A, Brant M, **Riesbeck K**, Azou Y, Forsgren A. 4-Quinolone antibiotics: positive genotoxic screening tests despite an apparent lack of mutation induction. *Mutat Res*. 1989 Mar;211(1):171-80. PubMed PMID: 2921999.
2. **Riesbeck K**, Andersson J, Gullberg M, Forsgren A. Fluorinated 4-quinolones induce hyperproduction of interleukin 2. *Proc Natl Acad Sci U S A*. 1989 Apr;86(8):2809-13. PubMed PMID: 2539601.
3. **Riesbeck K**, Bredberg A, Forsgren A. Ciprofloxacin does not inhibit mitochondrial functions but other antibiotics do. *Antimicrob Agents Chemother*. 1990 Jan;34(1):167-9. PubMed PMID: 2327755.
4. **Riesbeck K**, Forsgren A. Selective enhancement of synthesis of interleukin-2 in lymphocytes in the presence of ciprofloxacin. *Eur J Clin Microbiol Infect Dis*. 1990 Jun;9(6):409-13. PubMed PMID: 21175
5. Hansson BG, **Riesbeck K**, Nordenfelt E, Weiland O. Successful treatment of fulminant hepatitis B and fulminant hepatitis B and D coinfection explained by inhibitory effect on the immune response?. *Prog Clin Biol Res*. 1991;364:421-7. PubMed PMID: 1826956.
6. Ostraat O, Ekberg H, Schatz H, **Riesbeck K**, Eriksson T. Thalidomide prolongs graft survival in rat cardiac transplants. *Transplant Proc*. 1992 Dec;24(6):2624-5. PubMed PMID: 1465889.
7. Eriksson T, **Riesbeck K**, Ostraat O, Ekberg H, Björkman S. Drug exposure and flow cytometry analyses in a thalidomide treatment schedule that prolongs rat cardiac graft survival. *Transplant Proc*. 1992 Dec;24(6):2560-1. PubMed PMID: 1465866.
8. **Riesbeck K**, Schatz H, Ostraat O, Ekberg H, Forsgren A. Ciprofloxacin upregulates interleukin-2 at the protein and mRNA levels in murine lymphocytes, but does not shorten graft survival in a rat cardiac allograft transplantation model. *Transplant Proc*. 1992 Dec;24(6):2558-9. PubMed PMID: 1465865.
9. **Riesbeck K**, Gullberg M, Forsgren A. Evidence that the antibiotic ciprofloxacin counteracts cyclosporine-dependent suppression of cytokine production. *Transplantation*. 1994 Jan;57(2):267-72. PubMed PMID: 8310519.
10. **Riesbeck K**, Forsgren A. Increased interleukin 2 transcription in murine lymphocytes by ciprofloxacin. *Immunopharmacology*. 1994 Mar-Apr;27(2):155-64. PubMed PMID: 8014029
11. **Riesbeck K**, Forsgren A. Limited effects of temafloxacin compared with ciprofloxacin on T-lymphocyte function. *Antimicrob Agents Chemother*. 1994 Apr;38(4):879-82. PubMed PMID: 8031064.
12. **Riesbeck K**, Ekberg H, Forsgren A. Ciprofloxacin interferes with the immunosuppressive effects of cyclosporin A on cytokine production in vitro. *Transplant Proc*. 1994 Jun;26(3):1734-5. PubMed PMID: 8030110.
13. **Riesbeck K**, Sigvardsson M, Leanderson T, Forsgren A. Superinduction of cytokine gene transcription by ciprofloxacin. *J Immunol*. 1994 Jul 1;153(1):343-52. PubMed PMID: 8207247.
14. **Riesbeck K**, Schatz H, Ostraat O, Tufveson G, Forsgren A, Ekberg H. Enhancement of the immunosuppressive effect of cyclosporin A by ciprofloxacin in a rat cardiac allograft transplantation model. *Transpl Int*. 1995;8(2):96-102. PubMed PMID: 7766304.
15. **Riesbeck K**, Forsgren A. CP-115,953 stimulates cytokine production by lymphocytes. *Antimicrob Agents Chemother*. 1995 Feb;39(2):476-83. PubMed PMID: 7726518.
16. Ostraat O, **Riesbeck K**, Qi Z, Eriksson T, Schatz H, Ekberg H. Thalidomide prolonged graft survival in a rat cardiac transplant model but had no inhibitory effect on lymphocyte function in vitro. *Transpl Immunol*. 1996 Jun;4(2):117-25. PubMed PMID: 8843588.
17. Qi Z, **Riesbeck K**, Ostraat O, Tufveson G, Ekberg H. Single dose anti-CD4 monoclonal antibody for induction of tolerance to cardiac allograft in high- and low-responder rat strain combinations. *Transpl Immunol*. 1997 Sep;5(3):204-11. PubMed PMID: 9402687.

18. **Riesbeck K**, Dorling A, Kemball-Cook G, McVey JH, Jones M, Tuddenham EG, Lechler RI. Human tissue factor pathway inhibitor fused to CD4 binds both FXa and TF/FVIIa at the cell surface. *Thromb Haemost.* 1997 Dec;78(6):1488-94. PubMed PMID: 9423800.
19. **Riesbeck K**, Forsgren A. Commentary on ciprofloxacin-dependent superinduction of interleukin-2 synthesis and thymidine uptake. *Transplantation.* 1998 May 15;65(9):1282-3. PubMed PMID: 9603184.
20. Rosendahl A, Kristensson K, Hansson J, **Riesbeck K**, Kalland T, Dohlsten M. Perforin and IFN-gamma are involved in the antitumor effects of antibody-targeted superantigens. *J Immunol.* 1998 Jun 1;160(11):5309-13. PubMed PMID: 9605129.
21. **Riesbeck K**, Forsgren A, Henriksson A, Bredberg A. Ciprofloxacin induces an immunomodulatory stress response in human T lymphocytes. *Antimicrob Agents Chemother.* 1998 Aug;42(8):1923-30. PubMed PMID: 9687385.
22. **Riesbeck K**, Billström A, Tordsson J, Brodin T, Kristensson K, Dohlsten M. Endothelial cells expressing an inflammatory phenotype are lysed by superantigen-targeted cytotoxic T cells. *Clin Diagn Lab Immunol.* 1998 Sep;5(5):675-82. PubMed PMID: 9729535.
23. **Riesbeck K**, Chen D, Kemball-Cook G, McVey JH, George AJ, Tuddenham EG, Dorling A, Lechler RI. Expression of hirudin fusion proteins in mammalian cells: a strategy for prevention of intravascular thrombosis. *Circulation.* 1998 Dec 15;98(24):2744-52. PubMed PMID: 9851962.
24. **Riesbeck K**. Cisplatin at clinically relevant concentrations enhances interleukin-2 synthesis by human primary blood lymphocytes. *Anticancer Drugs.* 1999 Feb;10(2):219-27. PubMed PMID: 10211553.
25. Chen D, **Riesbeck K**, Kemball-Cook G, McVey JH, Tuddenham EG, Lechler RI, Dorling A. Inhibition of tissue factor-dependent and -independent coagulation by cell surface expression of novel anticoagulant fusion proteins. *Transplantation.* 1999 Feb 15;67(3):467-74. PubMed PMID: 10030296.
26. Rosendahl A, Kristensson K, Carlsson M, Skartved NJ, **Riesbeck K**, Søgaaard M, Dohlsten M. Long-term survival and complete cures of B16 melanoma-carrying animals after therapy with tumor-targeted IL-2 and SEA. *Int J Cancer.* 1999 Mar 31;81(1):156-63. PubMed PMID: 10077167.
27. Olsson C, **Riesbeck K**, Dohlsten M, Michaëlsson E. CTLA-4 ligation suppresses CD28-induced NF-kappaB and AP-1 activity in mouse T cell blasts. *J Biol Chem.* 1999 May 14;274(20):14400-5. PubMed PMID: 10318864.
28. **Riesbeck K**, Sanzén L. Destructive knee joint infection caused by *Peptostreptococcus micros*: importance of early microbiological diagnosis. *J Clin Microbiol.* 1999 Aug;37(8):2737-9. PubMed PMID: 10405436.
29. Chen D, **Riesbeck K**, McVey JH, Kemball-Cook G, Tuddenham EG, Lechler RI, Dorling A. Regulated inhibition of coagulation by porcine endothelial cells expressing P-selectin-tagged hirudin and tissue factor pathway inhibitor fusion proteins. *Transplantation.* 1999 Sep 27;68(6):832-9. PubMed PMID: 10515384.
30. Rosendahl A, Kristensson K, **Riesbeck K**, Dohlsten M. T-cell cytotoxicity assays for studying the functional interaction between the superantigen staphylococcal enterotoxin A and T-cell receptors. *Methods Mol Biol.* 2000;145:241-57. PubMed PMID: 10820726.
31. **Riesbeck K**, Orvelid-Mölling P, Fredlund H, Olcén P. Long-term persistence of a discotheque-associated invasive *Neisseria meningitidis* group C strain as proven by pulsed-field gel electrophoresis and *porA* gene sequencing. *J Clin Microbiol.* 2000 Apr;38(4):1638-40. PubMed PMID: 10747157.
32. Dorling A, Chen D, **Riesbeck K**, McVey J, Kemball-Cook G, Tuddenham EG, Lechler RI. Regulated endothelial cell expression of novel anticoagulants: a strategy for the prevention and therapy of intravascular thrombosis. *Transplant Proc.* 2000 Aug;32(5):971. PubMed PMID: 10936303.
33. Åhrén IL, Williams DL, Rice PJ, Forsgren A, **Riesbeck K**. The importance of a beta-glucan receptor in the nonopsonic entry of nontypeable *Haemophilus influenzae* into human monocytic and

- epithelial cells. *J Infect Dis*. 2001 Jul 15;184(2):150-8. PubMed PMID: 11424011.
34. Forsgren A, Brant M, Möllenkvist A, Muyombwe A, Janson H, Woin N, **Riesbeck K**. Isolation and characterization of a novel IgD-binding protein from *Moraxella catarrhalis*. *J Immunol*. 2001 Aug 15;167(4):2112-20. PubMed PMID: 11489995.
 35. Ahrén IL, Janson H, Forsgren A, **Riesbeck K**. Protein D expression promotes the adherence and internalization of non-typeable *Haemophilus influenzae* into human monocytic cells. *Microb Pathog*. 2001 Sep;31(3):151-8. PubMed PMID: 11500100.
 36. Lazou Ahrén I, Bjartell A, Egesten A, **Riesbeck K**. Lipopolysaccharide-binding protein increases toll-like receptor 4-dependent activation by nontypeable *Haemophilus influenzae*. *J Infect Dis*. 2001 Oct 1;184(7):926-30. PubMed PMID: 11528597.
 37. Chen D, **Riesbeck K**, McVey JH, Kembell-Cook G, Tuddenham EG, Lechler RI, Dorling A. Human thrombin and FXa mediate porcine endothelial cell activation; modulation by expression of TFPI-CD4 and hirudin-CD4 fusion proteins. *Xenotransplantation*. 2001 Nov;8(4):258-65. PubMed PMID: 11737851.
 38. Bråbäck M, **Riesbeck K**, Forsgren A. Susceptibilities of *Mycobacterium marinum* to gatifloxacin, gemifloxacin, levofloxacin, linezolid, moxifloxacin, telithromycin, and quinupristin-dalfopristin (Synercid) compared to its susceptibilities to reference macrolides and quinolones. *Antimicrob Agents Chemother*. 2002 Apr;46(4):1114-6. PubMed PMID: 11897601.
 39. Corbascio M, Ekstrand H, Osterholm C, Qi Z, Simanaitis M, Larsen CP, Pearson TC, **Riesbeck K**, Ekberg H. CTLA4Ig combined with anti-LFA-1 prolongs cardiac allograft survival indefinitely. *Transpl Immunol*. 2002 Jun;10(1):55-61. PubMed PMID: 12182466.
 40. Gjörloff Wingren A, Hadzic R, Forsgren A, **Riesbeck K**. The novel IgD binding protein from *Moraxella catarrhalis* induces human B lymphocyte activation and Ig secretion in the presence of Th2 cytokines. *J Immunol*. 2002 Jun 1;168(11):5582-8. PubMed PMID: 12023354.
 41. Björkman P, Nilsson A, **Riesbeck K**. A pilot with pain in his leg: thigh abscess caused by *Salmonella enterica* serotype Brandenburg. *J Clin Microbiol*. 2002 Sep;40(9):3530-1. PubMed PMID: 12202612.
 42. Nordström T, Forsgren A, **Riesbeck K**. The immunoglobulin D-binding part of the outer membrane protein MID from *Moraxella catarrhalis* comprises 238 amino acids and a tetrameric structure. *J Biol Chem*. 2002 Sep 20;277(38):34692-9. PubMed PMID: 12110669.
 43. Ahrén IL, Karlsson E, Forsgren A, **Riesbeck K**. Comparison of the antibacterial activities of ampicillin, ciprofloxacin, clarithromycin, telithromycin and quinupristin/dalfopristin against intracellular non-typeable *Haemophilus influenzae*. *J Antimicrob Chemother*. 2002 Dec;50(6):903-6. PubMed PMID: 12461011.
 44. Möllenkvist A, Nordström T, Halldén C, Christensen JJ, Forsgren A, **Riesbeck K**. The *Moraxella catarrhalis* immunoglobulin D-binding protein MID has conserved sequences and is regulated by a mechanism corresponding to phase variation. *J Bacteriol*. 2003 Apr;185(7):2285-95. PubMed PMID: 12644500.
 45. Forsgren A, Brant M, Karamehmedovic M, **Riesbeck K**. The immunoglobulin D-binding protein MID from *Moraxella catarrhalis* is also an adhesin. *Infect Immun*. 2003 Jun;71(6):3302-9. PubMed PMID: 12761112.
 46. Eriksson E, Forsgren A, **Riesbeck K**. Several gene programs are induced in ciprofloxacin-treated human lymphocytes as revealed by microarray analysis. *J Leukoc Biol*. 2003 Sep;74(3):456-63. PubMed PMID: 12949250.
 47. **Riesbeck K**. Paronychia due to *Prevotella bivia* that resulted in amputation: fast and correct bacteriological diagnosis is crucial. *J Clin Microbiol*. 2003 Oct;41(10):4901-3. PubMed PMID: 14532256.
 48. Ahrén IL, Eriksson E, Egesten A, **Riesbeck K**. Nontypeable *Haemophilus influenzae* activates human eosinophils through beta-glucan receptors. *Am J Respir Cell Mol Biol*. 2003 Nov;29(5):598-605. PubMed PMID: 12689921.
 49. Lanbeck P, Odenholt I, **Riesbeck K**. Dicloxacillin and erythromycin at high concentrations increase

- ICAM-1 expression by endothelial cells: a possible factor in the pathogenesis of infusion phlebitis. *J Antimicrob Chemother.* 2004 Feb;53(2):174-9. PubMed PMID: 14729754.
50. Forsgren A, Brant M, **Riesbeck K**. Immunization with the truncated adhesin moraxella catarrhalis immunoglobulin D-binding protein (MID764-913) is protective against M catarrhalis in a mouse model of pulmonary clearance. *J Infect Dis.* 2004 Jul 15;190(2):352-5. PubMed PMID: 15216472.
 51. Turesson C, **Riesbeck K**. Septicemia with Staphylococcus aureus, beta-hemolytic streptococci group B and G, and Escherichia coli in a patient with rheumatoid arthritis treated with a recombinant human interleukin 1 receptor antagonist (Anakinra). *J Rheumatol.* 2004 Sep;31(9):1876. PubMed PMID: 15338480.
 52. Nordström T, Blom AM, Forsgren A, **Riesbeck K**. The emerging pathogen Moraxella catarrhalis interacts with complement inhibitor C4b binding protein through ubiquitous surface proteins A1 and A2. *J Immunol.* 2004 Oct 1;173(7):4598-606. PubMed PMID: 15383594.
 53. Nielsen CK, Campbell JI, Ohd JF, Mörgelin M, **Riesbeck K**, Landberg G, Sjölander A. A novel localization of the G-protein-coupled CysLT1 receptor in the nucleus of colorectal adenocarcinoma cells. *Cancer Res.* 2005 Feb 1;65(3):732-42. PubMed PMID: 15705869.
 54. Hadzic R, Forsgren A, Cardell LO, **Riesbeck K**, Wingren AG. The CD19 molecule is crucial for MID-dependent activation of tonsillar B cells from children. *Scand J Immunol.* 2005 Feb;61(2):165-72. PubMed PMID: 15683453.
 55. Nordström T, Blom AM, Tan TT, Forsgren A, **Riesbeck K**. Ionic binding of C3 to the human pathogen Moraxella catarrhalis is a unique mechanism for combating innate immunity. *J Immunol.* 2005 Sep 15;175(6):3628-36. PubMed PMID: 16148107.
 56. Tan TT, Nordström T, Forsgren A, **Riesbeck K**. The respiratory pathogen Moraxella catarrhalis adheres to epithelial cells by interacting with fibronectin through ubiquitous surface proteins A1 and A2. *J Infect Dis.* 2005 Sep 15;192(6):1029-38. PubMed PMID: 16107956.
 57. Leandersson K, **Riesbeck K**, Andersson T. Wnt-5a mRNA translation is suppressed by the Elav-like protein HuR in human breast epithelial cells. *Nucleic Acids Res.* 2006;34(14):3988-99. PubMed PMID: 16914445.
 58. Nordström T, Jendholm J, Samuelsson M, Forsgren A, **Riesbeck K**. The IgD-binding domain of the Moraxella IgD-binding protein MID (MID962-1200) activates human B cells in the presence of T cell cytokines. *J Leukoc Biol.* 2006 Feb;79(2):319-29. PubMed PMID: 16301327.
 59. Hadzic R, Nita I, Tassidis H, **Riesbeck K**, Wingren AG, Janciauskiene S. Alpha1-antitrypsin inhibits Moraxella catarrhalis MID protein-induced tonsillar B cell proliferation and IL-6 release. *Immunol Lett.* 2006 Feb 15;102(2):141-7. PubMed PMID: 16214222.
 60. Hallström T, Trajkovska E, Forsgren A, **Riesbeck K**. Haemophilus influenzae surface fibrils contribute to serum resistance by interacting with vitronectin. *J Immunol.* 2006 Jul 1;177(1):430-6. PubMed PMID: 16785539.
 61. Pålman LI, Mörgelin M, Eckert J, Johansson L, Russell W, **Riesbeck K**, Soehnlein O, Lindbom L, Norrby-Teglund A, Schumann RR, Björck L, Herwald H. Streptococcal M protein: a multipotent and powerful inducer of inflammation. *J Immunol.* 2006 Jul 15;177(2):1221-8. PubMed PMID: 16818781.
 62. Tan TT, Forsgren A, **Riesbeck K**. The respiratory pathogen moraxella catarrhalis binds to laminin via ubiquitous surface proteins A1 and A2. *J Infect Dis.* 2006 Aug 15;194(4):493-7. PubMed PMID: 16845633.
 63. Samuelsson M, Jendholm J, Amisten S, Morrison SL, Forsgren A, **Riesbeck K**. The IgD CH1 region contains the binding site for the human respiratory pathogen Moraxella catarrhalis IgD-binding protein MID. *Eur J Immunol.* 2006 Sep;36(9):2525-34. PubMed PMID: 16906531.
 64. Tan TT, Christensen JJ, Dziegiel MH, Forsgren A, **Riesbeck K**. Comparison of the serological responses to Moraxella catarrhalis immunoglobulin D-binding outer membrane protein and the ubiquitous surface proteins A1 and A2. *Infect Immun.* 2006 Nov;74(11):6377-86. PubMed PMID: 16966403.
 65. Samuelsson M, Forsgren A, **Riesbeck K**. Purification of IgD from human serum--a novel application

- of recombinant M catarrhalis IgD-binding protein (MID). J Immunol Methods. 2006 Dec 20;317(1-2):31-7. PubMed PMID: 17056056.
66. Hallström T, Jarva H, **Riesbeck K**, Blom AM. Interaction with C4b-binding protein contributes to nontypeable Haemophilus influenzae serum resistance. J Immunol. 2007 May 15;178(10):6359-66. PubMed PMID: 17475865.
67. Samuelsson M, Hallström T, Forsgren A, **Riesbeck K**. Characterization of the IgD binding site of encapsulated Haemophilus influenzae serotype b. J Immunol. 2007 May 15;178(10):6316-9. PubMed PMID: 17475860.
68. Popadiak K, Potempa J, **Riesbeck K**, Blom AM. Biphasic effect of gingipains from Porphyromonas gingivalis on the human complement system. J Immunol. 2007 Jun 1;178(11):7242-50. PubMed PMID: 17513773.
69. Tan TT, Morgelin M, Forsgren A, **Riesbeck K**. Haemophilus influenzae survival during complement-mediated attacks is promoted by Moraxella catarrhalis outer membrane vesicles. J Infect Dis. 2007 Jun 1;195(11):1661-70. PubMed PMID: 17471436.
70. N'Guessan PD, Vigelahn M, Bachmann S, Zabel S, Opitz B, Schmeck B, Hippenstiel S, Zweigner J, **Riesbeck K**, Singer BB, Suttorp N, Slevogt H. The UspA1 protein of Moraxella catarrhalis induces CEACAM-1-dependent apoptosis in alveolar epithelial cells. J Infect Dis. 2007 Jun 1;195(11):1651-60. PubMed PMID: 17471435.
71. **Riesbeck K**, Hammas B. Comparison of an automated Borrelia indirect chemiluminescent immunoassay (CLIA) with a VlsE/C6 ELISA and Immunoblot. Eur J Clin Microbiol Infect Dis. 2007 Jul;26(7):517-9. PubMed PMID: 17558488.
72. Ronander E, Brant M, Janson H, Sheldon J, Forsgren A, **Riesbeck K**. Identification of a novel Haemophilus influenzae protein important for adhesion to epithelial cells. Microbes Infect. 2008 Jan;10(1):87-96. PubMed PMID: 18069033.
73. Hallström T, Müller SA, Mörgelin M, Möllenkvis A, Forsgren A, **Riesbeck K**. The Moraxella IgD-binding protein MID/Hag is an oligomeric autotransporter. Microbes Infect. 2008 Apr;10(4):374-81. PubMed PMID: 18400547.
74. Manolov T, Forsgren A, **Riesbeck K**. Purification of alpha1-antichymotrypsin from human plasma with recombinant M catarrhalis ubiquitous surface protein A1. J Immunol Methods. 2008 Apr 20;333(1-2):180-5. PubMed PMID: 18242635.
75. Manolov T, Tan TT, Forsgren A, **Riesbeck K**. Moraxella-dependent alpha 1-antichymotrypsin neutralization: a unique virulence mechanism. Am J Respir Cell Mol Biol. 2008 May;38(5):609-17. PubMed PMID: 18096871.
76. Jendholm J, Samuelsson M, Cardell LO, Forsgren A, **Riesbeck K**. Moraxella catarrhalis-dependent tonsillar B cell activation does not lead to apoptosis but to vigorous proliferation resulting in nonspecific IgM production. J Leukoc Biol. 2008 Jun;83(6):1370-8. PubMed PMID: 18372337.
77. Hallström T, Zipfel PF, Blom AM, Lauer N, Forsgren A, **Riesbeck K**. Haemophilus influenzae interacts with the human complement inhibitor factor H. J Immunol. 2008 Jul 1;181(1):537-45. PubMed PMID: 18566420.
78. Potempa M, Potempa J, Okroj M, Popadiak K, Eick S, **Riesbeck K**, Blom AM. Binding of complement inhibitor C4b-binding protein contributes to serum resistance of Porphyromonas gingivalis. J Immunol. 2008 Oct 15;181(8):5537-44. PubMed PMID: 18832711.
79. Slevogt H, Zabel S, Opitz B, Hocke A, Eitel J, Eitel J, N'guessan PD, Lucka L, **Riesbeck K**, Zimmermann W, Zweigner J, Temmesfeld-Wollbrueck B, Suttorp N, Singer BB. CEACAM1 inhibits Toll-like receptor 2-triggered antibacterial responses of human pulmonary epithelial cells. Nat Immunol. 2008 Nov;9(11):1270-8. PubMed PMID: 18836450.
80. Potempa M, Potempa J, Kantyka T, Nguyen KA, Wawrzonek K, **Riesbeck K**, Blom AM. Interpain A, a cysteine proteinase from Prevotella intermedia, inhibits complement by degrading complement factor C3. PLoS Pathog. 2009 Feb;5(2):e1000316. PubMed PMID: 19247445.
81. Ronander E, Brant M, Eriksson E, Mörgelin M, Hallgren O, Westergren-Thorsson G, Forsgren A, **Riesbeck K**. Nontypeable Haemophilus influenzae adhesin protein E: characterization and

- biological activity. *J Infect Dis.* 2009 Feb 15;199(4):522-31. PubMed PMID: 19125675.
82. Jendholm J, Mörgelin M, Perez Vidakovics ML, Carlsson M, Leffler H, Cardell LO, **Riesbeck K**. Superantigen- and TLR-dependent activation of tonsillar B cells after receptor-mediated endocytosis. *J Immunol.* 2009 Apr 15;182(8):4713-20. PubMed PMID: 19342647.
 83. Dieudonné-Vatran A, Krentz S, Blom AM, Meri S, Henriques-Normark B, **Riesbeck K**, Albiger B. Clinical isolates of *Streptococcus pneumoniae* bind the complement inhibitor C4b-binding protein in a PspC allele-dependent fashion. *J Immunol.* 2009 Jun 15;182(12):7865-77. PubMed PMID: 19494311.
 84. Chen K, Xu W, Wilson M, He B, Miller NW, Bengtén E, Edholm ES, Santini PA, Rath P, Chiu A, Cattalini M, Litzman J, Bussell J, Huang B, Meini A, **Riesbeck K**, Cunningham-Rundles C, Plebani A, Cerutti A. Immunoglobulin D enhances immune surveillance by activating antimicrobial, proinflammatory and B cell-stimulating programs in basophils. *Nat Immunol.* 2009 Aug;10(8):889-98. PubMed PMID: 19561614.
 85. Hallström T, Blom AM, Zipfel PF, **Riesbeck K**. Nontypeable *Haemophilus influenzae* protein E binds vitronectin and is important for serum resistance. *J Immunol.* 2009 Aug 15;183(4):2593-601. PubMed PMID: 19635912.
 86. Rydberg C, Månsson A, Uddman R, **Riesbeck K**, Cardell LO. Toll-like receptor agonists induce inflammation and cell death in a model of head and neck squamous cell carcinomas. *Immunology.* 2009 Sep;128(1 Suppl):e600-11. PubMed PMID: 19740321.
 87. Vidakovics ML, Jendholm J, Mörgelin M, Månsson A, Larsson C, Cardell LO, **Riesbeck K**. B cell activation by outer membrane vesicles - a novel virulence mechanism. *PLoS Pathog.* 2010 Jan 15;6(1):e1000724.
 88. Singh B, Brant M, Kilian M, Hallström B, **Riesbeck K**. Protein E of *Haemophilus influenzae* is a ubiquitous highly conserved adhesin. *J Infect Dis.* 2010 Feb 1;201(3):414-9.
 89. Singh B, Blom AM, Unal C, Nilsson B, Mörgelin M, **Riesbeck K**. Vitronectin binds to the head region of *Moraxella catarrhalis* ubiquitous surface protein A2 and confers complement-inhibitory activity. *Mol Microbiol.* 2010 Mar;75(6):1426-44.
 90. Hallström T, Resman F, Ristovski M, **Riesbeck K**. Binding of complement regulators to invasive nontypeable *Haemophilus influenzae* isolates is not increased compared to nasopharyngeal isolates, but serum resistance is linked to disease severity. *J Clin Microbiol.* 2010 Mar;48(3):921-7.
 91. de Vries SP, van Hijum SA, Schueler W, **Riesbeck K**, Hays JP, Hermans PW, Bootsma HJ. Genome analysis of *Moraxella catarrhalis* strain BBH18, a human respiratory tract pathogen. *J Bacteriol.* 2010 Jul;192(14):3574-83.
 92. Petterson T, Jendholm J, Månsson A, Bjartell A, **Riesbeck K**, Cardell LO. Effects of NOD-like receptors in human B lymphocytes and crosstalk between NOD1/NOD2 and Toll-like receptors. *J Leukoc Biol.* 2011 Feb;89(2):177-87.
 93. Hallström T, Nordström T, Tan TT, Manolov T, Lambris JD, Isenman DE, Zipfel PF, Blom AM, **Riesbeck K**. Immune evasion of *Moraxella catarrhalis* involves ubiquitous surface protein A-dependent C3d binding. *J Immunol.* 2011 Mar 1;186(5):3120-9.
 94. Schaar V, de Vries SP, Perez Vidakovics ML, Bootsma HJ, Larsson L, Hermans PW, Bjartell A, Mörgelin M, **Riesbeck K**. Multicomponent *Moraxella catarrhalis* outer membrane vesicles induce an inflammatory response and are internalized by human epithelial cells. *Cell Microbiol.* 2011 Mar;13(3):432-49.
 95. Petterson T, Månsson A, **Riesbeck K**, Cardell LO. Nucleotide-binding and oligomerization domain-like receptors and retinoic acid inducible gene-like receptors in human tonsillar T lymphocytes. *Immunology.* 2011 May;133(1):84-93.
 96. Karlsson J, Andréasson B, Kondori N, Erman E, **Riesbeck K**, Høgevik H, Wennerås C. Comparative study of immune status to infectious agents in elderly patients with multiple myeloma, Waldenström's macroglobulinemia, and monoclonal gammopathy of undetermined significance. *Clin Vaccine Immunol.* 2011 Jun;18(6):969-77.
 97. Saleh K, Sonesson A, Persson B, **Riesbeck K**, Schmidtchen A. A descriptive study of bacterial load

- of full-thickness surgical wounds in dermatologic surgery. *Dermatol Surg*. 2011 Jul;37(7):1014-22.
98. Singh B, Jalalvand F, Mörgelin M, Zipfel P, Blom AM, **Riesbeck K**. Haemophilus influenzae protein E recognizes the C-terminal domain of vitronectin and modulates the membrane attack complex. *Mol Microbiol*. 2011 Jul;81(1):80-98.
 99. Schaar V, Nordström T, Mörgelin M, **Riesbeck K**. Moraxella catarrhalis outer membrane vesicles carry β -lactamase and promote survival of Streptococcus pneumoniae and Haemophilus influenzae by inactivating amoxicillin. *Antimicrob Agents Chemother*. 2011 Aug;55(8):3845-53.
 100. Verhaegh SJ, de Vogel CP, **Riesbeck K**, Lafontaine ER, Murphy TF, et al. Temporal development of the humoral immune response to surface antigens of Moraxella catarrhalis in young infants. *Vaccine*. 2011 Aug 5;29(34):5603-10.
 101. Hallström T, Singh B, Resman F, Blom AM, Mörgelin M, **Riesbeck K**. Haemophilus influenzae protein E binds to the extracellular matrix by concurrently interacting with laminin and vitronectin. *J Infect Dis*. 2011 Oct 1;204(7):1065-74.
 102. Resman F, Ristovski M, Ahl J, Forsgren A, Gilsdorf JR, **Riesbeck K**. Invasive disease caused by Haemophilus influenzae in Sweden 1997-2009; evidence of increasing incidence and clinical burden of non-type b strains. *Clin Microbiol Infect*. 2011 Nov;17(11):1638-45.
 103. Resman F, Svensjö T, Ünal C, Cronqvist J, Brorson H, Odenholt I, **Riesbeck K**. Necrotizing myositis and septic shock caused by Haemophilus influenzae type f in a previously healthy man diagnosed with an IgG3 and a mannose-binding lectin deficiency. *Scand J Infect Dis*. 2011 Dec;43(11-12):972-6.
 104. Millrud CR, Månsson Kvarnhammar A, Uddman R, Björnsson S, **Riesbeck K**, Cardell LO. The activation pattern of blood leukocytes in head and neck squamous cell carcinoma is correlated to survival. *PLoS One*. 2012;7(12):e51120.
 105. Malm S, Jusko M, Eick S, Potempa J, **Riesbeck K**, Blom AM. Acquisition of complement inhibitor serine protease factor I and its cofactors C4b-binding protein and factor H by Prevotella intermedia. *PLoS One*. 2012;7(4):e34852.
 106. Barthel D, Singh B, **Riesbeck K**, Zipfel PF. Haemophilus influenzae uses the surface protein E to acquire human plasminogen and to evade innate immunity. *J Immunol*. 2012 Jan 1;188(1):379-85.
 107. Singh B, Al Jubair T, Förnvik K, Thunnissen MM, **Riesbeck K**. Crystallization and X-ray diffraction analysis of a novel surface-adhesin protein: protein E from Haemophilus influenzae. *Acta Crystallogr Sect F Struct Biol Cryst Commun*. 2012 Feb 1;68(Pt 2):222-6.
 108. Jusko M, Potempa J, Karim AY, Ksiazek M, **Riesbeck K**, Garred P, Eick S, Blom AM. A metalloproteinase karilysin present in the majority of Tannerella forsythia isolates inhibits all pathways of the complement system. *J Immunol*. 2012 Mar 1;188(5):2338-49.
 109. Verhaegh SJ, Stol K, de Vogel CP, **Riesbeck K**, Lafontaine ER, et al. Comparative analysis of the humoral immune response to Moraxella catarrhalis and Streptococcus pneumoniae surface antigens in children suffering from recurrent acute otitis media and chronic otitis media with effusion. *Clin Vaccine Immunol*. 2012 Jun;19(6):914-8.
 110. Resman F, Ristovski M, Forsgren A, Kaijser B, Kronvall G, Medstrand P, Melander E, Odenholt I, **Riesbeck K**. Increase of β -lactam-resistant invasive Haemophilus influenzae in Sweden, 1997 to 2010. *Antimicrob Agents Chemother*. 2012 Aug;56(8):4408-15.
 111. Agarwal V, Hammerschmidt S, Malm S, Bergmann S, **Riesbeck K**, et al. Enolase of Streptococcus pneumoniae binds human complement inhibitor C4b-binding protein and contributes to complement evasion. *J Immunol*. 2012 Oct 1;189(7):3575-84.
 112. Unal CM, Singh B, Fleury C, Singh K, Chávez de Paz L, Svensäter G, **Riesbeck K**. QseC controls biofilm formation of non-typeable Haemophilus influenzae in addition to an AI-2-dependent mechanism. *Int J Med Microbiol*. 2012 Nov;302(6):261-9.
 113. Zomer A, de Vries SP, **Riesbeck K**, Meinke AL, Hermans PW, Bootsma HJ. Genome sequence of Moraxella catarrhalis RH4, an isolate of seroresistant lineage. *J Bacteriol*. 2012 Dec;194(24):6969.
 114. Su YC, Jalalvand F, Mörgelin M, Blom AM, Singh B, **Riesbeck K**. Haemophilus influenzae acquires vitronectin via the ubiquitous Protein F to subvert host innate immunity. *Mol Microbiol*.

- 2013 Mar;87(6):1245-66.
115. Singh B, Al-Jubair T, Mörgelin M, Thunnissen MM, **Riesbeck K**. The unique structure of Haemophilus influenzae protein E reveals multiple binding sites for host factors. Infect Immun. 2013 Mar;81(3):801-14.
116. Jalalvand F, Su YC, Mörgelin M, Brant M, Hallgren O, Westergren-Thorsson G, Singh B, **Riesbeck K**. Haemophilus influenzae protein F mediates binding to laminin and human pulmonary epithelial cells. J Infect Dis. 2013 Mar 1;207(5):803-13.
117. Schaar V, Paulsson M, Mörgelin M, **Riesbeck K**. Outer membrane vesicles shield Moraxella catarrhalis β -lactamase from neutralization by serum IgG. J Antimicrob Chemother. 2013 Mar;68(3):593-600.
118. Agarwal V, Kuchipudi A, Fulde M, **Riesbeck K**, Bergmann S, Blom AM. Streptococcus pneumoniae endopeptidase O (PepO) is a multifunctional plasminogen- and fibronectin-binding protein, facilitating evasion of innate immunity and invasion of host cells. J Biol Chem. 2013 Mar 8;288(10):6849-63.
119. Su YC, Hallström BM, Bernhard S, Singh B, **Riesbeck K**. Impact of sequence diversity in the Moraxella catarrhalis UspA2/UspA2H head domain on vitronectin binding and antigenic variation. Microbes Infect. 2013 May;15(5):375-87.
120. Voss S, Hallström T, Saleh M, Burchhardt G, Pribyl T, Singh B, **Riesbeck K**, Zipfel PF, Hammerschmidt S. The choline-binding protein PspC of Streptococcus pneumoniae interacts with the C-terminal heparin-binding domain of vitronectin. J Biol Chem. 2013 May 31;288(22):15614-27.
121. Su YC, Hörhold F, Singh B, **Riesbeck K**. Complete Genome Sequence of Encapsulated Haemophilus influenzae Type f KR494, an Invasive Isolate That Caused Necrotizing Myositis. Genome Announc. 2013 Oct 3;1(5).
122. Agarwal V, Ahl J, **Riesbeck K**, Blom AM. An alternative role of C1q in bacterial infections: facilitating Streptococcus pneumoniae adherence and invasion of host cells. J Immunol. 2013 Oct 15;191(8):4235-45.
123. Ahl J, Littorin N, Forsgren A, Odenholt I, Resman F, **Riesbeck K**. High incidence of septic shock caused by Streptococcus pneumoniae serotype 3--a retrospective epidemiological study. BMC Infect Dis. 2013 Oct 22;13:492.
124. Lopez CM, Wallich R, **Riesbeck K**, Skerka C, Zipfel PF. Candida albicans uses the surface protein Gpm1 to attach to human endothelial cells and to keratinocytes via the adhesive protein vitronectin. PLoS One. 2014;9(3):e90796.
125. Schaar V, Uddbäck I, Nordström T, **Riesbeck K**. Group A streptococci are protected from amoxicillin-mediated killing by vesicles containing β -lactamase derived from Haemophilus influenzae. J Antimicrob Chemother. 2014 Jan;69(1):117-20.
126. Su YC, Resman F, Hörhold F, **Riesbeck K**. Comparative genomic analysis reveals distinct genotypic features of the emerging pathogen Haemophilus influenzae type f. BMC Genomics. 2014 Jan 18;15:38.
127. Jalalvand F, Littorin N, Su YC, **Riesbeck K**. Impact of immunization with Protein F on pulmonary clearance of nontypeable Haemophilus influenzae. Vaccine. 2014 Apr 25;32(20):2261-4.
128. Ahl J, Melander E, Odenholt I, Tvetman L, Thörnblad T, **Riesbeck K**, Ringberg H. Risk factors for pneumococcal carriage in day care centers: a retrospective study during a 10-year period. Pediatr Infect Dis J. 2014 May;33(5):536-8.
129. Fleury C, Resman F, Rau J, **Riesbeck K**. Prevalence, distribution and transfer of small β -lactamase-containing plasmids in Swedish Haemophilus influenzae. J Antimicrob Chemother. 2014 May;69(5):1238-42.
130. Singh K, Nordström T, Mörgelin M, Brant M, Cardell LO, **Riesbeck K**. Haemophilus influenzae resides in tonsils and uses immunoglobulin D binding as an evasion strategy. J Infect Dis. 2014 May 1;209(9):1418-28.
131. Agarwal V, Sroka M, Fulde M, Bergmann S, **Riesbeck K**, Blom AM. Binding of Streptococcus

- pneumoniae endopeptidase O (PepO) to complement component C1q modulates the complement attack and promotes host cell adherence. *J Biol Chem*. 2014 May 30;289(22):15833-44.
132. Singh B, Su YC, Al-Jubair T, Mukherjee O, Hallström T, Mörgelin M, Blom AM, **Riesbeck K**. A fine-tuned interaction between trimeric autotransporter haemophilus surface fibrils and vitronectin leads to serum resistance and adherence to respiratory epithelial cells. *Infect Immun*. 2014 Jun;82(6):2378-89.
 133. Deknuydt F, Nordström T, **Riesbeck K**. Diversion of the host humoral response: a novel virulence mechanism of *Haemophilus influenzae* mediated via outer membrane vesicles. *J Leukoc Biol*. 2014 Jun;95(6):983-91.
 134. Fleury C, Su YC, Hallström T, Sandblad L, Zipfel PF, **Riesbeck K**. Identification of a *Haemophilus influenzae* factor H-Binding lipoprotein involved in serum resistance. *J Immunol*. 2014 Jun 15;192(12):5913-23.
 135. Al Jubair T, Singh B, Fleury C, Blom AM, Mörgelin M, Thunnissen MM, **Riesbeck K**. *Haemophilus influenzae* stores and distributes hemin by using protein E. *Int J Med Microbiol*. 2014 Jul;304(5-6):662-8.
 136. Barfod A, Singh B, Johanson U, **Riesbeck K**, Kjellbom P. In vitro selection of RNA aptamers directed against protein E: a *Haemophilus influenzae* adhesin. *Mol Biotechnol*. 2014 Aug;56(8):714-25.
 137. Bernhard S, Fleury C, Su YC, Zipfel PF, Koske I, Nordström T, **Riesbeck K**. Outer membrane protein OlpA contributes to *Moraxella catarrhalis* serum resistance via interaction with factor H and the alternative pathway. *J Infect Dis*. 2014 Oct 15;210(8):1306-10.
 138. Blom AM, Bergmann S, Fulde M, **Riesbeck K**, Agarwal V. *Streptococcus pneumoniae* phosphoglycerate kinase is a novel complement inhibitor affecting the membrane attack complex formation. *J Biol Chem*. 2014 Nov 21;289(47):32499-511.
 139. Hallström T, Uhde M, Singh B, Skerka C, **Riesbeck K**, Zipfel PF. *Pseudomonas aeruginosa* Uses Dihydrolipoamide Dehydrogenase (Lpd) to Bind to the Human Terminal Pathway Regulators Vitronectin and Clusterin to Inhibit Terminal Pathway Complement Attack. *PLoS One*. 2015;10(9):e0137630.
 140. Mukherjee O, Singh B, Bayrak B, Jonsson AB, Mörgelin M, **Riesbeck K**. A fusion protein derived from *Moraxella catarrhalis* and *Neisseria meningitidis* aimed for immune modulation of human B cells. *Hum Vaccin Immunother*. 2015;11(9):2223-7.
 141. Abdillahi SM, Bober M, Nordin S, Hallgren O, Baumgarten M, Erjefält J, Westergren-Thorsson G, Bjermer L, **Riesbeck K**, Egesten A, Mörgelin M. Collagen VI Is Upregulated in COPD and Serves Both as an Adhesive Target and a Bactericidal Barrier for *Moraxella catarrhalis*. *J Innate Immun*. 2015;7(5):506-17.
 142. Singh B, Jubair TA, Mörgelin M, Sundin A, Linse S, Nilsson UJ, **Riesbeck K**. *Haemophilus influenzae* surface fibril (Hsf) is a unique twisted hairpin-like trimeric autotransporter. *Int J Med Microbiol*. 2015 Jan;305(1):27-37.
 143. Kohler S, Hallström T, Singh B, **Riesbeck K**, Sparta G, Zipfel PF, Hammerschmidt S. Binding of vitronectin and Factor H to Hic contributes to immune evasion of *Streptococcus pneumoniae* serotype 3. *Thromb Haemost*. 2015 Jan;113(1):125-42.
 144. Ahl J, Melander E, Odenholt I, Tvetman L, Thörnblad T, **Riesbeck K**, Ringberg H. Prevalence of penicillin-non-susceptible *Streptococcus pneumoniae* in children in day-care centres subjected to an intervention to prevent dispersion. *Infect Dis (Lond)*. 2015 May;47(5):338-44.
 145. Månsson V, Resman F, Kostrzewa M, Nilson B, **Riesbeck K**. Identification of *Haemophilus influenzae* Type b Isolates by Use of Matrix-Assisted Laser Desorption Ionization-Time of Flight Mass Spectrometry. *J Clin Microbiol*. 2015 Jul;53(7):2215-24.
 146. Gutbier B, Fischer K, Doehn JM, von Lachner C, Herr C, Klaile E, Frischmann U, Singer BB, **Riesbeck K**, Zimmermann W, Suttorp N, Bachmann S, Bals R, Witzernath M, Slevogt H. *Moraxella catarrhalis* induces an immune response in the murine lung that is independent of human

- CEACAM5 expression and long-term smoke exposure. *Am J Physiol Lung Cell Mol Physiol*. 2015 Aug 1;309(3):L250-61.
147. Jusko M, Potempa J, Mizgalska D, Bielecka E, Ksiazek M, **Riesbeck K**, Garred P, Eick S, Blom AM. A Metalloproteinase Mirolysin of *Tannerella forsythia* Inhibits All Pathways of the Complement System. *J Immunol*. 2015 Sep 1;195(5):2231-40.
 148. Singh B, Al-Jubair T, Voraganti C, Andersson T, Mukherjee O, Su YC, Zipfel P, **Riesbeck K**. *Moraxella catarrhalis* Binds Plasminogen To Evade Host Innate Immunity. *Infect Immun*. 2015 Sep;83(9):3458-69.
 149. Paulsson M, Singh B, Al-Jubair T, Su YC, Høiby N, **Riesbeck K**. Identification of outer membrane Porin D as a vitronectin-binding factor in cystic fibrosis clinical isolates of *Pseudomonas aeruginosa*. *J Cyst Fibros*. 2015 Sep;14(5):600-7.
 150. Al-Jubair T, Mukherjee O, Oosterhuis S, Singh B, Su YC, Fleury C, Blom AM, Törnroth-Horsefield S, **Riesbeck K**. *Haemophilus influenzae* Type f Hijacks Vitronectin Using Protein H To Resist Host Innate Immunity and Adhere to Pulmonary Epithelial Cells. *J Immunol*. 2015 Dec 15;195(12):5688-95.
 151. Andersson M, Resman F, Eitrem R, Drobni P, **Riesbeck K**, Kahlmeter G, Sundqvist M. Outbreak of a beta-lactam resistant non-typeable *Haemophilus influenzae* sequence type 14 associated with severe clinical outcomes. *BMC Infect Dis*. 2015 Dec 23;15:581.
 152. Hallström T, Singh B, Kraiczy P, Hammerschmidt S, Skerka C, Zipfel PF, **Riesbeck K**. Conserved Patterns of Microbial Immune Escape: Pathogenic Microbes of Diverse Origin Target the Human Terminal Complement Inhibitor Vitronectin via a Single Common Motif. *PLoS One*. 2016;11(1):e0147709.
 153. Su YC, Mukherjee O, Singh B, Hallgren O, Westergren-Thorsson G, Hood D, **Riesbeck K**. *Haemophilus influenzae* P4 Interacts With Extracellular Matrix Proteins Promoting Adhesion and Serum Resistance. *J Infect Dis*. 2016 Jan 15;213(2):314-23.
 154. Liu G, Gradstedt H, Ermert D, Englund E, Singh B, Su YC, Johansson ME, Aspberg A, Agarwal V, **Riesbeck K**, Blom AM. *Moraxella catarrhalis* Evades Host Innate Immunity via Targeting Cartilage Oligomeric Matrix Protein. *J Immunol*. 2016 Feb 1;196(3):1249-58.
 155. Aung KM, Sjöström AE, von Pawel-Rammingen U, **Riesbeck K**, Uhlin BE, Wai SN. Naturally Occurring IgG Antibodies Provide Innate Protection against *Vibrio cholerae* Bacteremia by Recognition of the Outer Membrane Protein U. *J Innate Immun*. 2016;8(3):269-83.
 156. Singh B, Alvarado-Kristensson M, Johansson M, Hallgren O, Westergren-Thorsson G, Mörgelin M, **Riesbeck K**. The Respiratory Pathogen *Moraxella catarrhalis* Targets Collagen for Maximal Adherence to Host Tissues. *mBio*. 2016 Mar 22;7(2).
 157. Richter C, Mukherjee O, Ermert D, Singh B, Su YC, Agarwal V, Blom AM, **Riesbeck K**. Moonlighting of *Helicobacter pylori* catalase protects against complement-mediated killing by utilising the host molecule vitronectin. *Sci Rep*. 2016 Apr 18;6:24391
 158. Heinrich A, Heyl KA, Klaile E, Müller MM, Klassert TE, Wiessner A, Fischer K, Schumann RR, Seifert U, **Riesbeck K**, Moter A, Singer BB, Bachmann S, Slevogt H. *Moraxella catarrhalis* induces CEACAM3-Syk-Card9-dependent activation of human granulocytes. *Cell Microbiol*. 2016 Mar 31.
 159. Resman F, Thegerström J, Månsson F, Ahl J, Tham J, **Riesbeck K**. The prevalence, population structure and screening test specificity of penicillin-susceptible *Staphylococcus aureus* bacteremia isolates in Malmö, Sweden. *J Infect*. 2016 Aug;73(2):129-35.
 160. Littorin N, Ahl J, Uddén F, Resman F, **Riesbeck K**. Reduction of *Streptococcus pneumoniae* in upper respiratory tract cultures and a decreased incidence of related acute otitis media following introduction of childhood pneumococcal conjugate vaccines in a Swedish county. *BMC Infect Dis*. 2016 Aug 11;16(1):407.
 161. Jusko M, Miedziak B, Ermert D, Magda M, King BC, Bielecka E, **Riesbeck K**, Eick S, Potempa J, Blom AM. FACIN, a Double-Edged Sword of the Emerging Periodontal Pathogen *Filifactor alocis*: A Metabolic Enzyme Moonlighting as a Complement Inhibitor. *J Immunol*. 2016 Oct 15;197(8):3245-3259.

162. Saleh K, Sonesson A, Persson K, **Riesbeck K**, Schmidtchen A. Can dressings soaked with polyhexanide reduce bacterial loads in full-thickness skin grafting? A randomized controlled trial. *J Am Acad Dermatol*. 2016 Dec;75(6):1221-1228.e4.
163. Heinrich A, Heyl KA, Klaile E, Müller MM, Klassert TE, Wiessner A, Fischer K, Schumann RR, Seifert U, **Riesbeck K**, Moter A, Singer BB, Bachmann S, Slevogt H. *Moraxella catarrhalis* induces CEACAM3-Syk-CARD9-dependent activation of human granulocytes. *Cell Microbiol*. 2016 Nov;18(11):1570-1582.
164. Mühlenkamp MC, Hallström T, Autenrieth IB, Bohn E, Linke D, Rinker J, **Riesbeck K**, Singh B, Leo JC, Hammerschmidt S, Zipfel PF, Schütz MS. Vitronectin Binds to a Specific Stretch within the Head Region of Yersinia Adhesin A and Thereby Modulates *Yersinia enterocolitica* Host Interaction. *J Innate Immun*. 2017;9(1):33-51.
165. **Riesbeck K**. Inhaled Corticosteroids in Chronic Obstructive Pulmonary Disease. A Two-Edged Sword. *Am J Respir Crit Care Med*. 2016 Nov 15;194(10):1177-1178.
166. Månsson V, Skaare D, **Riesbeck K**, Resman F. The spread and clinical impact of ST14CC-PBP3 type IIb/A, a clonal group of non-typeable *Haemophilus influenzae* with chromosomally mediated β -lactam resistance-a prospective observational study. *Clin Microbiol Infect*. 2017 Mar;23(3):209.e1-209.e7.
167. Paulsson M, Granrot A, Ahl J, Tham J, Resman F, **Riesbeck K**, Månsson F. Antimicrobial combination treatment including ciprofloxacin decreased the mortality rate of *Pseudomonas aeruginosa* bacteraemia: a retrospective cohort study. *Eur J Clin Microbiol Infect Dis*. 2017 Jul;36(7):1187-1196.
168. Liu G, Ermer D, Johansson ME, Singh B, Su YC, Paulsson M, **Riesbeck K**, Blom AM. PRELP Enhances Host Innate Immunity against the Respiratory Tract Pathogen *Moraxella catarrhalis*. *J Immunol*. 2017 Mar 15;198(6):2330-2340.
169. Wright J, Thomsen M, Kolodziejczyk R, Ridley J, Sinclair J, Carrington G, Singh B, **Riesbeck K**, Goldman A. The crystal structure of PD1, a *Haemophilus* surface fibril domain. *Acta Crystallogr F Struct Biol Commun*. 2017 Feb 1;73(Pt 2):101-108.
170. Fish AI, Riley SP, Singh B, **Riesbeck K**, Martinez JJ. The Rickettsia conorii Adr1 Interacts with the C-Terminus of Human Vitronectin in a Salt-Sensitive Manner. *Front Cell Infect Microbiol*. 2017 Mar 1;7:61. doi: 10.3389/fcimb.2017.00061. eCollection 2017.
171. Filipe M, Reimer Å, Matuschek E, Paul M, Pelkonen T, **Riesbeck K**. Fluoroquinolone-Resistant *Alcaligenes faecalis* Related to Chronic Suppurative Otitis Media, Angola. *Emerg Infect Dis*. 2017 Oct;23(10):1740-1742.
172. Su YC, Halang P, Fleury C, Jalalvand F, Mörgelin M, **Riesbeck K**. *Haemophilus* Protein F Orthologs of Pathogens Infecting the Airways: Exploiting Host Laminin at Heparin-Binding Sites for Maximal Adherence to Epithelial Cells. *J Infect Dis*. 2017 Dec 5;216(10):1303-1307.
173. **Riesbeck K**. Hemolytic Uremic Syndrome Associated With Pneumococci in Children-An Elusive Mystery Now Explained? *J Infect Dis*. 2018 Jan 17;217(3):341-343.
174. van den Heuvel L, **Riesbeck K**, El Tahir O, Gracchi V, Kremlitzka M, Morré SA, van Furth AM, Singh B, Okrój M, van de Kar N, Blom AM, Volokhina E. Genetic predisposition to infection in a case of atypical hemolytic uremic syndrome. *J Hum Genet*. 2018 Jan;63(1):93-96.
175. Månsson V, Gilsdorf JR, Kahlmeter G, Kilian M, Kroll JS, **Riesbeck K**, Resman F. Capsule Typing of *Haemophilus influenzae* by Matrix-Assisted Laser Desorption/Ionization Time-of-Flight Mass Spectrometry. *Emerg Infect Dis*. 2018 Mar;24(3):443-452.
176. Uddén F, Filipe M, Reimer Å, Paul M, Matuschek E, Thegerström J, Hammerschmidt S, Pelkonen T, **Riesbeck K**. Aerobic bacteria associated with chronic suppurative otitis media in Angola. *Infect Dis Poverty*. 2018 May 3;7(1):42.
177. Ohlin A, Mattsson E, Mörgelin M, Davies JR, Svensäter G, Corvec S, Tengvall P, **Riesbeck K**. Titanium granules pre-treated with hydrogen peroxide inhibit growth of bacteria associated with post-operative infections in spine surgery. *Eur Spine J*. 2018 Oct;27(10):2463-2468.
178. Thegerström J, Matuschek E, Su YC, **Riesbeck K**, Resman F. A novel PBP3 substitution in

- Haemophilus influenzae* confers reduced aminopenicillin susceptibility. BMC Microbiol. 2018 May 31;18(1):48.
179. Thegerström J, Månsson V, **Riesbeck K**, Resman F. Benzylpenicillin versus wide-spectrum beta-lactam antibiotics as empirical treatment of *Haemophilus influenzae*-associated lower respiratory tract infections in adults; a retrospective propensity score-matched study. Eur J Clin Microbiol Infect Dis. 2018 Sep;37(9):1761-1775.
 180. Paulsson M, Che KF, Ahl J, Tham J, Sandblad L, Smith ME, Qvarfordt I, Su YC, Lindén A, **Riesbeck K**. Bacterial Outer Membrane Vesicles Induce Vitronectin Release Into the Bronchoalveolar Space Conferring Protection From Complement-Mediated Killing. Front Microbiol. 2018 Jul 13;9:1559.
 181. Lekmeechai S, Su YC, Brant M, Alvarado-Kristensson M, Vallström A, Obi I, Arnqvist A, **Riesbeck K**. *Helicobacter pylori* Outer Membrane Vesicles Protect the pathogen From Reactive Oxygen Species of the Respiratory Burst. Front Microbiol. 2018 Sep 7;9:1837.
 182. Laabei M, Liu G, Ermer D, Lambris JD, **Riesbeck K**, Blom AM. Short Leucine-Rich Proteoglycans Modulate Complement Activity and Increase Killing of the Respiratory Pathogen *Moraxella catarrhalis*. J Immunol. 2018 Nov 1;201(9):2721-2730.
 183. Singh B, Mostajeran M, Su YC, Al-Jubair T, **Riesbeck K**. Assays for Studying the Role of Vitronectin in Bacterial Adhesion and Serum Resistance. J Vis Exp. 2018 Oct 16;(140).
 184. Resman F, Manat G, Lindh V, Murphy TF, **Riesbeck K**. Differential distribution of IgA-protease genotypes in mucosal and invasive isolates of *Haemophilus influenzae* in Sweden. BMC Infect Dis. 2018 Nov 22;18(1):592.
 185. Littorin N, Uddén F, Ahl J, Resman F, Slotved HC, Athlin S, **Riesbeck K**. Serotypes With Low Invasive Potential Are Associated With an Impaired Antibody Response in Invasive Pneumococcal Disease. Front Microbiol. 2018 Nov 15;9:2746.
 186. Thofter O, Kaur R, Su YC, Brant M, Rudin A, Hood D, **Riesbeck K**. Anti-EF-Tu IgG titers increase with age and may contribute to protection against the respiratory pathogen *Haemophilus influenzae*. Eur J Immunol. 2019 Mar;49(3):490-499.
 187. Thofter O, Su YC, Brant M, Littorin N, Duell BL, Alvarado V, Jalalvand F, **Riesbeck K**. EF-Tu From Non-typeable *Haemophilus influenzae* Is an Immunogenic Surface-Exposed Protein Targeted by Bactericidal Antibodies. Front Immunol. 2018 Dec 18;9:2910.
 188. Holmdahl T, Odenholt I, **Riesbeck K**, Medstrand P, Widell A. Hydrogen peroxide vapour treatment inactivates norovirus but has limited effect on post-treatment viral RNA levels. Infect Dis (Lond). 2019 Mar;51(3):197-205.
 189. Rodríguez-Arce I, Al-Jubair T, Euba B, Fernández-Calvet A, Gil-Campillo C, Martí S, Törnroth-Horsefield S, **Riesbeck K**, Garmendia J. Moonlighting of *Haemophilus influenzae* heme acquisition systems contributes to the host airway-pathogen interplay in a coordinated manner. Virulence. 2019 Dec;10(1):315-333.
 190. Stephan JG, Lamei S, Pettis JS, **Riesbeck K**, de Miranda JR, Forsgren E. Honeybee-Specific Lactic Acid Bacterium Supplements Have No Effect on American Foulbrood-Infected Honeybee Colonies. Appl Environ Microbiol. 2019 Jun 17;85(13).
 191. Su YC, Mattsson E, Singh B, Jalalvand F, Murphy TF, **Riesbeck K**. The Laminin Interactome: A Multifactorial Laminin-Binding Strategy by Nontypeable *Haemophilus influenzae* for Effective Adherence and Colonization. J Infect Dis. 2019 Aug 9;220(6):1049-1060.
 192. Saleh K, Strömdahl AC, **Riesbeck K**, Schmidtchen A. Inflammation Biomarkers and Correlation to Wound Status After Full-Thickness Skin Grafting. Front Med (Lausanne). 2019 Jul 12;6:159.
 193. Ljungquist O, Schönbeck M, **Riesbeck K**, Tham J. Risk factors associated with prolonged intestinal colonization of ESBL-producing *Enterobacteriaceae* – a prospective cohort study. Infect Drug Resist. 2019 Aug 26;12:2637-2648.
 194. Lamei S, Stephan JG, Nilson B, Sieuwerts S, **Riesbeck K**, de Miranda JR, Forsgren E. Feeding Honeybee Colonies with Honeybee-Specific Lactic Acid Bacteria (Hbs-LAB) Does Not Affect Colony-Level Hbs-LAB Composition or *Paenibacillus larvae* Spore Levels, Although American Foulbrood Affected Colonies Harbor a More Diverse Hbs-LAB Community. Microb Ecol. 2019 Sep 10. doi:

- 10.1007/s00248-019-01434-3.
195. Ljungquist O, Kampmann C, Resman F, **Riesbeck K**, Tham J. Probiotics for intestinal decolonization of ESBL-producing *Enterobacteriaceae*: a randomized, placebo-controlled clinical trial. Clin Microbiol Infect. 2019 Sep 5. pii: S1198-743X(19)30481-1.
196. Alamiri F, **Riesbeck K**, Hakansson AP. HAMLET, a protein complex from human milk has bactericidal activity and enhances the activity of antibiotics against pathogenic *Streptococci*. Antimicrob Agents Chemother. 2019 Oct 7. pii: AAC.01193-19.
197. Bettoni S, Shaughnessy J, Maziarz K, Ermert D, Gulati S, Zheng B, Mörgelin M, Jacobsson S, **Riesbeck K**, Unemo M, Ram S, Blom AM. C4BP-IgM protein as a therapeutic approach to treat *Neisseria gonorrhoeae* infections. JCI Insight. 2019 Dec 5;4(23). pii: 131886.
198. Paulsson M, Su YC, Ringwood T, Uddén F, **Riesbeck K**. *Pseudomonas aeruginosa* uses multiple receptors for adherence to laminin during infection of the respiratory tract and skin wounds. Sci Rep. 2019 Dec 3;9(1):18168.
199. Uddén F, Ahl J, Littorin N, Strålin K, Athlin S, **Riesbeck K**. A Nonfunctional Opsonic Antibody Response Frequently Occurs after Pneumococcal Pneumonia and Is Associated with Invasive Disease. mSphere. 2020 Feb 5;5(1). pii: e00925-19. doi: 10.1128/mSphere.00925-19.
200. Byström E, Lindstrand A, Bergström J, **Riesbeck K**, Roth A. Confidence in the National Immunization Program among parents in Sweden 2016 - A cross-sectional survey. Vaccine. 2020 Feb 11. pii: S0264-410X(20)30120-1. doi:10.1016/j.vaccine.2020.01.078.
201. Idahl A, Cornet CL, Maldonado SG, Waterboer T, Bender N, Tjønneland A, Hansen L, Boutron-Ruault MC, Fournier A, Kvaskoff M, Boeing H, Trichopoulou A, Valanou E, Peppas E, Palli D, Agnoli C, Mattiello A, Tumino R, Sacerdote C, Onland-Moret NC, Gram IT, Weiderpass E, Quirós JR, Duell EJ, Sánchez MJ, Chirlaque MD, Barricarte A, Gil L, Brändstedt J, **Riesbeck K**, Lundin E, Khaw KT, Perez-Cornago A, Gunter MJ, Dossus L, Kaaks R, Fortner RT. Serologic markers of Chlamydia trachomatis and other sexually transmitted infections and subsequent ovarian cancer risk: Results from the EPIC cohort. Int J Cancer. 2020 Apr 3. doi:10.1002/ijc.32999.
202. Littorin N, Rünow E, Ahl J, Resman F, **Riesbeck K**. Decreased prevalence of *Moraxella catarrhalis* in addition to *Streptococcus pneumoniae* in children with upper respiratory tract infection after introduction of conjugated pneumococcal vaccine: a retrospective cohort study. Clin Microbiol Infect. 2020 Apr 30;S1198-743X(20)30259-7. doi: 10.1016/j.cmi.2020.04.033.
203. Alamiri F, Chao Y, Baumgarten M, **Riesbeck K**, Hakansson AP A Role of Epithelial Cells and Virulence Factors in Biofilm Formation by *Streptococcus pyogenes* In Vitro. Infect Immun. 2020 Sep 18;88(10):e00133-20. doi: 10.1128/IAI.00133-20.
204. Filipe M, Karppinen M, Kumatoko P, Reimer Å, **Riesbeck K**, Pelkonen T. Suppurative otitis media in Angola: clinical and demographic features. Trop Med Int Health. 2020 Jul 17. doi: 10.1111/tmi.13466.
205. Mehmeti-Ajradini M, Bergenfelz C, Larsson AM, Carlsson R, **Riesbeck K**, Ahl J, Janols H, Wullt M, Bredberg A, Källberg E, Björk Gunnarsdóttir F, Rydberg Millrud C, Rydén L, Paul G, Loman N, Adolfsson J, Carneiro A, Jirström K, Killander F, Bexell D, Leandersson K. Human G-MDSCs are neutrophils at distinct maturation stages promoting tumor growth in breast cancer. Life Sci Alliance. 2020 Sep 21;3(11):e202000893. doi: 10.26508/lsa.202000893.
206. Laabei M, Colineau L, Bettoni S, Maziarz K, Ermert D, **Riesbeck K**, Ram S, Blom AM. Antibacterial Fusion Proteins Enhance *Moraxella catarrhalis* Killing. Front Immunol. 2020 Sep 2;11:2122. doi: 10.3389/fimmu.2020.02122.
207. Ljungquist O, Camporeale A, Nematzadeh S, Giske CG, Resman F, **Riesbeck K***, Tham J*. ESBL-producing *Enterobacterales* in patients with traveller's diarrhoea - a cross sectional cohort study. Antimicrob Agents Chemother. 2020 Sep 28;AAC.01585-20. doi: 10.1128/AAC.01585-20. *these authors have an equal contribution.
208. Uddén F, Ahl J, Littorin N, Strålin K, Athlin S, **Riesbeck K**. mSphere. Corrected and Republished from: A Nonfunctional Opsonic Antibody Response Frequently Occurs after Pneumococcal Pneumonia and Is Associated with Invasive Disease. 2020 Dec 16;5(6):e01102-20. doi:

- 10.1128/mSphere.
209. Colineau L, Laabei M, Liu G, Ermert D, Lambris JD, **Riesbeck K**, Blom AM. Interaction of *Streptococcus pyogenes* with extracellular matrix components resulting in immunomodulation and bacterial eradication. *Matrix Biol Plus*. 2020 Jan 13;6-7:100020.
 210. Sahlström T, Ljungquist O, Su YC, Resman F, Mattsson E, Tham J, **Riesbeck K**. Bacteremia with ESBL-producing Enterobacterales is associated with IgG antibodies reacting with CTX-M-15 and/or CTX-M-27. *Int J Med Microbiol*. 2020 Dec;310(8):151468.
 211. Paulsson M, Kragh KN, Su YC, Sandblad L, Singh B, Bjarnsholt T, **Riesbeck K**. Peptidoglycan-Binding Anchor Is a *Pseudomonas aeruginosa* OmpA Family Lipoprotein With Importance for Outer Membrane Vesicles, Biofilms, and the Periplasmic Shape. *Front Microbiol*. 2021 Feb 25;12:639582.
 212. Paulsson M, Thelaus L, **Riesbeck K**, Qvarfordt I, Smith ME, Lindén A, Linder A. Heparin-binding protein in lower airway samples as a biomarker for pneumonia. *Respir Res*. 2021 Jun 8;22(1):174.
 213. Uddén F, Rünow E, Slotved HC, Fuursted K, Ahl J, **Riesbeck K**. Characterization of *Streptococcus pneumoniae* detected in clinical respiratory tract samples in southern Sweden 2 to 4 years after introduction of PCV13. *J Infect*. 2021 Aug;83(2):190-196.
 214. Thofte O, Bettoni S, Su YC, Thegerström J, Jonsson S, Mattsson E, Sandblad L, Martí S, Garmendia J, Blom AM, **Riesbeck K**. Nontypeable *Haemophilus influenzae* P5 Binds Human C4b-Binding Protein, Promoting Serum Resistance. *J Immunol*. 2021 Aug 25;ji2100105.
 215. Che KF, Paulsson M, Piersiala K, Sax J, Mboob I, Rahman M, Rekha RS, Säfholm J, Adner M, Bergman P, Cardell LO, **Riesbeck K**, Lindén A. Complex Involvement of Interleukin-26 in Bacterial Lung Infection. *Front Immunol*. 2021 Oct 28;12:761317. doi: 10.3389/fimmu.2021.761317. eCollection 2021.
 216. Magda M, Bettoni S, Laabei M, Fairley D, Russo TA, **Riesbeck K**, Blom AM. Clinical Isolates of *Acinetobacter* spp. Are Highly Serum Resistant Despite Efficient Recognition by the Complement System. *Front Immunol*. 2022 Jan 31;13:814193. doi: 10.3389/fimmu.2022.814193.
 217. Ljungquist O, Persmark A, Grabe M, Jakobsen AK, Gerdtsen A, Torisson G, Bjartell A[#], **Riesbeck K[#]**. Increasing rates of urinary and bloodstream infections following transrectal prostate biopsy in South Sweden. *BJU Int*. 2022 Feb 16. doi: 10.1111/bju.15713. [#]equal contribution.
 218. Yamba Yamba L, Uddén F, Fuursted K, Ahl J, Slotved HC, **Riesbeck K**. Extensive/Multidrug-Resistant Pneumococci Detected in Clinical Respiratory Tract Samples in Southern Sweden Are Closely Related to International Multidrug-Resistant Lineages. *Front Cell Infect Microbiol*. 2022 Mar 22;12:824449. doi: 10.3389/fcimb.2022.824449.
 219. Jalalvand F, Su YC, Manat G, Chernobrovkin A, Kadari M, Jonsson S, Janousková M, Rutishauser D, Semsey S, Løbner-Olesen A, Sandblad L, Flärdh K, Mengin-Lecreulx D, Zubarev RA, **Riesbeck K**. Protein domain-dependent vesiculation of Lipoprotein A, a protein that is important in cell wall synthesis and fitness of the human respiratory pathogen *Haemophilus influenzae*. *Front Cell Infect Microbiol*. 2022 Oct 7;12:984955. doi: 10.3389/fcimb.2022.984955.
 220. Hansen K, Runow, Torisson G, Theilacker C, Palmborg A, Pan K, Jiang Q, Southern J, Beavon R, Gessner B, **Riesbeck K[#]**, Ahl J[#]. Pneumococcal etiology and serotype distribution among adults hospitalized with radiographically confirmed Community-Acquired Pneumonia in Sweden, 2016-2018. 2023. *Frontiers in Public Health*. 2023 Feb 17;11:1086648. doi: 10.3389/fpubh.2023.1086648. [#]equal contribution and corresponding authors.
 221. Jalalvand F, Su YC, Manat G, Chernobrovkin A, Kadari M, Jonsson S, Janousková M, Rutishauser D, Semsey S, Løbner-Olesen A, Sandblad L, Flärdh K, Mengin-Lecreulx D, Zubarev RA, **Riesbeck K**. Protein domain-dependent vesiculation of Lipoprotein A, a protein that is important in cell wall synthesis and fitness of the human respiratory pathogen *Haemophilus influenzae*. *Front Cell Infect Microbiol*. 2022 Oct 7;12:984955. doi: 10.3389/fcimb.2022.984955.
 222. Su Yu-Ching, Kadari M, Straw ML, Janoušková M, Jonsson S, Thofte O, Jalalvand F, Matuschek E, Sandblad L, Végvári A, Zubarev RA, **Riesbeck K**. Non-typeable *Haemophilus influenzae* major outer membrane protein P5 contributes to bacterial membrane stability, and affects the membrane protein composition crucial for interactions with the human host. 2023. *Front Cell*

- Infect Microbiol. 2023 May 26;13:1085908. doi: 10.3389/fcimb.2023.1085908.
223. Ljungquist O, Nazarchuk O, Kahlmeter G, Andrews V, Koitan T, Wasserstrom L, Dmytriiev D, Fomina N, Bebyk V, Matuschek E, **Riesbeck K**. Highly multidrug-resistant Gram-negative bacterial infections in war victims — Ukraine, 2022. *Lancet Infectious Diseases, Research Letter*. 2023 Jul;23(7):784-786. doi: 10.1016/S1473-3099(23)00291-8.
224. Appelqvist E, Danielsson M, Jama A, Ask LS, Stenhammar C, Lindstrand A, **Riesbeck K**, Roth A. Parental views and the key role of nurses for high vaccine acceptance in Sweden - a focus group study. *BMC Public Health*. 2023 Sep 14;23(1):1786. doi: 10.1186/s12889-023-16678-5.
225. Hansen K, Yamba Yamba L, Wasserstrom L, Rünow E, Göransson T, Nilsson A, Ahl J, **Riesbeck K**. Exploring the microbial landscape: uncovering the pathogens associated with community-acquired pneumonia in hospitalized patients. *Front Public Health*. 2023 Dec 13;11:1258981. doi: 10.3389/fpubh.2023.1258981.
226. Jørgensen J, Dahlman D, Alanko Blomé M, Janson H, **Riesbeck K**, Nilsson AC. *Staphylococcus aureus* carriage and prevalence of skin and soft tissue infections among people who inject drugs: a longitudinal study. *Sci Rep*. 2024 Jun 5;14(1):12919.
227. Yamba Yamba L, Hansen K, Wasserstrom L, Ahl J, **Riesbeck K**. The importance of *Haemophilus influenzae* in community-acquired pneumonia: an emerging pathogen in the elderly regardless of comorbidities compared to *Streptococcus pneumoniae*. *Pneumonia* 2024 Aug 25;16(1):15. doi: 10.1186/s41479-024-00136-w.
228. Ljungquist O, Magda M, Giske CG, Tellapragada C, Nazarchuk O, Dmytriiev D, Thofte O, Öhnström V, Matuschek E, Blom AM, **Riesbeck K**. Pandrug -resistant *Klebsiella pneumoniae* isolated from Ukrainian war victims are hypervirulent. *J Infect*. 2024 Dec;89(6):106312. doi: 10.1016/j.jinf.2024.106312.
229. Bettoni S, Dziedzic M, Bierschenk D, Chrobak M, Magda M, Laabei M, King BC, **Riesbeck K**, Blom AM. C4b-Binding Protein and Factor H Attenuate NLRP3 Inflammasome-Mediated Signalling Response during Group A Streptococci Infection in Human Cells. *J Innate Immun*. 2024;16(1):554-572. doi: 10.1159/000542434.
230. Holmberg P, Janoušková M, Schmidt T, Neumann A, Olsson O, Isberg PE, Reimann M, **Riesbeck K**, Skogmar S, Björkman P. Blood levels of Mycobacterium tuberculosis (Mtb)antigen-triggered immune markers in people exposed to tuberculosis with regard to Mtb infection status and receipt of tuberculosis preventive therapy. *Tuberculosis (Edinb)*. 2024 Dec 20;151:102595.
231. Rünow E, Valeur F, Torisson G, Hansen K, Theilacker C, **Riesbeck K**, Ahl J. The incidence of radiologically verified community-acquired pneumonia requiring hospitalisation in adults living in southern Sweden, 2016-2018: a population-based study. *BMC Infect Dis*. 2025 Jan 17;25(1):80. doi: 10.1186/s12879-025-10468-7.
232. Magda M, Boschloo W, Bettoni S, Fairley D, Russo TA, Giske CG, Tellapragada C, Rooijackers SHM, **Riesbeck K**, Blom AM. *Acinetobacter baumannii* clinical isolates resist complement-mediated lysis by inhibiting the complement cascade and improperly depositing MAC. *J Innate Immun*. 2025 Jan 22:1-20. doi: 10.1159/000543664.
233. Lindström L, Zhou J, Villoutreix BO, Malycheva D, Otrocka M, Gustavsson AL, Lundbäck T, Bliman D, Shameem MA, Straw M, **Riesbeck K**, Olsson R, Alvarado-Kristensson M. Targeting TUBG1 in RB1-negative tumors. *FASEB J*. 2025 Mar 15;39(5):e70431. doi: 10.1096/fj.202403180RR.
234. Boattini M, Bianco G, Bastos P, Mavromanolaki VE, Maraki S, Spiliopoulou A, Kakouris V, Kalchev Y, Budimir A, Bedenić B, Rubic Z, Licker M, Musuroi C, Juhász E, Kristóf K, Pirs M, Velimirovic I, Berktoold M, Liptáková A, Krajcikova A, Drevinek P, Gryndlerova A, Brzychczy-Wloch M, Olechowska-Jarząb A, Bielec F, Brauncajs M, Podsiadly E, Nurzyńska G, Zalas-Więcek P, **Riesbeck K**, Andersson HS, Tønjum T, Berild JC, Leegaard TM, Rasmussen AN, Schønning K, Glöckner S, Rödel J, Badr MT, Häcker GA, Stark D, Hamprecht A, Dudakova A, Jantsch J, Mancini S, Quiblier C, Jacot D, Greub G, Ferniani T, Ambretti S, Calvo M, Stefani S, Schade R, Yusuf E, Koeveringe SVK, Vandamme S, Verroken A, Rodriguez-Villalobos H, Duigou F, Corvec S, Floch P, Massip C, Chainier D, Barraud O, Louissaint MB, Mizrahi A, Ali S, Doyle M, Egan C, McNicholas S, Colomina-Rodriguez

- J, Torres I, Luengo RG, Escartín MNL, Perez MBV, Halperin AV, García SF, Cantón R, Seruca M, Mendes VS, Carvalho D, Cavallo R, Cristino JM, Costa C. [Diagnostic and epidemiological landscape of anaerobic bacteria in Europe, 2020-2023 \(ANAEuROBE\)](#). *Int J Antimicrob Agents*. 2025 Feb 28;107478. doi: 10.1016/j.ijantimicag.2025.
235. Lofton-Tomenius H, Pang Y, Pallin A, Myktybekova Z, Lelham N, **Riesbeck K**, Vågesjö E, Roos S, Phillipson M. In Vitro Elimination of Highly Multidrug-Resistant Bacteria by the Lactic Acid Bacterial Drug Candidate ILP100. *Infect Dis Ther*. 2025 Mar 31. doi: 10.1007/s40121-025-01137-y.
236. Zubiria-Barrera C, Yamba LY, Klassert TE, Bos M, Ahl J, Wasserstrom L, Slevogt H[#], **Riesbeck K[#]**. Profiling the nasopharyngeal Microbiome in patients with community-acquired pneumonia caused by *Streptococcus pneumoniae*: diagnostic challenges and ecological insights. *Med Microbiol Immunol*. 2025 Apr 10;214(1):19. doi: 10.1007/s00430-025-00828-0.
[#]equal contribution and corresponding authors.
237. Månsson TS, Askemyr A, Sunnerhagen T, Tham J, **Riesbeck K**, Mellhammar L. Piperacillin/tazobactam versus carbapenems for 30-day mortality in patients with ESBL-producing Enterobacterales bloodstream infections: a retrospective, multicenter, non-inferiority, cohort study. *Infection*. 2025 Apr 16. doi: 10.1007/s15010-025-02496-x.
238. Lokras A, Baghel S, Thakur A, Jensen RF, Thanthrige MP, Thofte O, Rosenkrands I, **Riesbeck K**, Franzky H, Rades T, Paludan SR, Christensen D, Pedersen GK, Foged C. Cholesterol in mRNA-lipid nanoparticles can be replaced with the synthetic mycobacterial monomycoloyl analogue MMG-1, *Ad. Functional Materials*, in press, 2025.

2. Reviews and Book chapters (n=36)

1. Forsgren A, Bredberg A, **Riesbeck K**. Effect of ciprofloxacin on human lymphocytes--laboratory studies. *Scand J Infect Dis Suppl*. 1989;60:39-45. PubMed PMID: 2667107.
2. Forsgren A, Bredberg A, **Riesbeck K**. New quinolones: in vitro effects as a potential source of clinical toxicity. *Rev Infect Dis*. 1989 Jul-Aug;11 Suppl 5:S1382-9. PubMed PMID: 2549607.
3. Dorling A, **Riesbeck K**, and Lechler RI. The T-cell response to xenografts: molecular interactions and graft-specific immunosuppression. *Xeno* **4**: 68-76 (1996).
4. Dorling A, **Riesbeck K**, Warrens A, Lechler R. Clinical xenotransplantation of solid organs. *Lancet*. 1997 Mar 22;349(9055):867-71. PubMed PMID: 9121275.
5. Rosendahl A, Kristensson K, **Riesbeck K**, and Dohlsten M. Superantigen-dependent cytotoxicity. *Methods Molecular and Biology* **145**: 241-257 (2000).
6. **Riesbeck K**. Effects of quinolone antibiotics on the immune system. *The Journal of Chemotherapy* **14**: 3-12 (2002).
7. **Riesbeck K**. Immunomodulating activity of quinolones: review. *J Chemother*. 2002 Feb;14(1):3-12. PubMed PMID: 11892896.
8. **Riesbeck K**. Immunomodulation by fluoroquinolones and other antibacterial agents. *Eur J Clin Invest*. 2006 Oct;36(10):671-3. PubMed PMID: 16968461.
9. **Riesbeck K**, Nordstrom T. Structure and immunological action of the human pathogen *Moraxella catarrhalis* IgD-binding protein. *Crit Rev Immunol*. 2006;26(4):353-76. PubMed PMID: 17073558.
10. **Riesbeck K**, Tan TT, Forsgren A. MID and UspA1/A2 of the human respiratory pathogen *Moraxella catarrhalis*, and interactions with the human host as basis for vaccine development. *Acta Biochim Pol*. 2006;53(3):445-56. PubMed PMID: 16964325.
11. Tan TT, **Riesbeck K**. Current progress of adhesins as vaccine candidates for *Moraxella catarrhalis*. *Expert Rev Vaccines*. 2007 Dec;6(6):949-56. PubMed PMID: 18377357.
12. Forsgren A, **Riesbeck K**, Janson H. Protein D of *Haemophilus influenzae*: a protective nontypeable H influenzae antigen and a carrier for pneumococcal conjugate vaccines. *Clin Infect Dis*. 2008 Mar 1;46(5):726-31. PubMed PMID: 18230042.
13. Perez Vidakovics ML, **Riesbeck K**. Virulence mechanisms of *Moraxella* in the pathogenesis of infection. *Curr Opin Infect Dis*. 2009 Jun;22(3):279-85. PubMed PMID: 19405217.
14. Blom AM, Hallström T, **Riesbeck K**. Complement evasion strategies of pathogens-acquisition of

- inhibitors and beyond. *Mol Immunol*. 2009 Sep;46(14):2808-17. PubMed PMID: 19477524.
15. Hallström T, **Riesbeck K**. *Haemophilus influenzae* and the complement system. *Trends Microbiol*. 2010 Jun;18(6):258-65.
 16. Singh B, Su YC, **Riesbeck K**. Vitronectin in bacterial pathogenesis: a host protein used in complement escape and cellular invasion. *Mol Microbiol*. 2010 Nov;78(3):545-60.
 17. Singh B, Su YC, **Riesbeck K**. Vitronectin in host pathogen interactions and antimicrobial therapeutic applications. *Cent. Eur. J. Biol*. 2011 6(6):973-980.
 18. Unal CM, Schaar V, **Riesbeck K**. Bacterial outer membrane vesicles in disease and preventive medicine. *Semin Immunopathol*. 2011 Sep;33(5):395-408.
 19. Singh K, Bayrak B, **Riesbeck K**. A role for TLRs in *Moraxella*-superantigen induced polyclonal B cell activation. *Front Biosci (Schol Ed)*. 2012 Jan 1;4:1031-43.
 20. Su YC, Singh B, **Riesbeck K**. *Moraxella catarrhalis*: from interactions with the host immune system to vaccine development. *Future Microbiol*. 2012 Sep;7(9):1073-100.
 21. Singh B, Fleury C, Jalalvand F, **Riesbeck K**. Human pathogens utilize host extracellular matrix proteins laminin and collagen for adhesion and invasion of the host. *FEMS Microbiol Rev*. 2012 Nov;36(6):1122-80.
 22. **Riesbeck K**. *Candida albicans* is a crafty microbe that deceives its host by using complement regulators and proteases. *J Infect Dis*. 2013 Feb 15;207(4):550-2.
 23. Zipfel PF, Hallström T, **Riesbeck K**. Human complement control and complement evasion by pathogenic microbes--tipping the balance. *Mol Immunol*. 2013 Dec 15;56(3):152-60.
 24. Verhaegh, SJC, Schaar V, Yu Ching S, **Riesbeck K**, Hays JP. Respiratory tract infections, Part 14, *Moraxella catarrhalis*. In *Molecular Medical Microbiology*, Volume 1, (2014), Elsevier.
 25. Jalalvand F, **Riesbeck K**. *Haemophilus influenzae*: recent advances in the understanding of molecular pathogenesis and polymicrobial infections. *Curr Opin Infect Dis*. 2014 Jun;27(3):268-74.
 26. Duell BL, Su YC, **Riesbeck K**. Host-pathogen interactions of nontypeable *Haemophilus influenzae*: from commensal to pathogen. *FEBS Lett*. 2016 Nov;590(21):3840-3853. PMID: 27508518.
 27. The complement inhibitor vitronectin. Su Y-C and **Riesbeck K**. In. "The Complements Factsbook", 2nd edition, by Barnum S and Ramos T, Eds., Elsevier, accepted for publication (2017).
 28. Jalalvand F, **Riesbeck K**. Update on non-typeable *Haemophilus influenzae*-mediated disease and vaccine development. *Expert Rev Vaccines*. 2018 Jun;17(6):503-512.
 29. Paulsson M, **Riesbeck K**. How bacteria hack the matrix and dodge the bullets of immunity. *Eur Respir Rev*. 2018 Jun 27;27(148).
 30. Soares RP, Xander P, Costa AO, Marcilla A, Menezes-Neto A, Del Portillo H, Witwer K, Wauben M, Nolte-T Hoen E, Olivier M, Criado MF, da Silva LLP, Abdel Baqui MM, Schenkman S, Colli W, Alves MJM, Ferreira KS, Puccia R, Nejsun P, **Riesbeck K**, Stensballe A, Hansen EP, Jaular LM, Øvstebø R, de la Canal L, Bergese P, Pereira-Chiocola V, Pfaffl MW, Fritz J, Ghossein YS, Torrecilhas AC. Highlights of the São Paulo ISEV workshop on extracellular vesicles in cross-kingdom communication. *J Extracell Vesicles*. 2017 Nov 26;6(1):1407213.
 31. Su YC, Jalalvand F, Thegerström J, **Riesbeck K**. The Interplay Between Immune Response and Bacterial Infection in COPD: Focus Upon Non-typeable *Haemophilus influenzae*. *Front Immunol*. 2018 Nov 5;9:2530.
 32. Thornton RB, Hakansson A, Hood DW, Nokso-Koivisto J, Preciado D, **Riesbeck K**, Richmond PC, Su YC, Swords WE, Brockman KL. Panel 7 - Pathogenesis of otitis media - a review of the literature between 2015 and 2019. *Int J Pediatr Otorhinolaryngol*. 2020 Mar;130 Suppl 1:109838. doi: 10.1016/j.ijporl.2019.109838.
 33. **Riesbeck K**. Complement evasion by the human respiratory tract pathogens *Haemophilus influenzae* and *Moraxella catarrhalis*. *FEBS Lett*. 2020 Aug;594(16):2586-2597. doi: 10.1002/1873-3468.13758.
 34. Janouskova M, Straw ML, Su YS, **Riesbeck K**. Gene Expression Regulation in Airway Pathogens: Importance for Otitis Media. *Front Cell Infect Microbiol*. 2022 Feb 11;12:826018.

35. **Riesbeck K.** *Haemophilus influenzae* and *H. ducreyi*. In Mandell, Principles and Practices of Infectious Diseases, revised version 2024.
36. **Riesbeck K** and Muphy T. *Haemophilus species* and *Moraxella catarrhalis*. In Harrison, Internal Medicine, revised version 2024.

3. Patents

1. Inventors: **Riesbeck K**, Dorling A, George A, and Lechler RI. US patent no. 6,423,316 B1 (Jul 23, 2002). Title: 'Anticoagulant fusion proteins anchored to cell membrane', RPMS, Hammersmith Hospital, London, UK.
2. Inventors: Forsgren A, Janson H, and **Riesbeck K**. Application No./ Patent No. 02741607.2-2405-SE0201299 (2001). Title: 'Novel surface exposed immunoglobulin D-binding protein from *M. catarrhalis*'.
3. Inventors: Forsgren A and **Riesbeck K**. Application No./ Patent No. 60/707 148. (2005) Title: 'Interaction of *Moraxella catarrhalis* with epithelial cells, extracellular matrix proteins and the complement system'. European Union and North America. This patent has also been filed in the following countries: Algeria, Australia, Brazil, Canada, China, Colombia, Egypt, India, Indonesia, Israel, Japan, Malaysia, Mexico, Morocco, New Zealand, Nigeria, Norway, Philippines, Republic of Korea, Singapore, South Africa, Trinidad & Tobago, Ukraine, Hong Kong.
4. Inventors: Forsgren A and **Riesbeck K**. Application No./ Patent No. SE-21023113/ (2006), US 2009/0246219 (Oct. 1, 2009). Title: '*Haemophilus influenzae* Protein E (PE) Is a Novel Adhesin with the Active Binding Site within the Central Part of the Molecule'. European Union and North America. This patent has also been filed in the following countries: Algeria, Australia, Brazil, Canada, China, Colombia, Egypt, India, Indonesia, Israel, Japan, Malaysia, Mexico, Morocco, New Zealand, Nigeria, Norway, Philippines, Republic of Korea, Singapore, South Africa, Trinidad & Tobago, Ukraine, Hong Kong.
5. Inventors: **Riesbeck K** and Yu-Ching Su. Application No./ Patent No. 61/484 697, US (2011). Title: Protein F – a novel *Haemophilus influenzae* adhesin with laminin and vitronectin binding properties.

4. Popular science publications including books/ presentations (mostly in Swedish)

1. **Riesbeck K.** Forskningsdag, Lunds Universitet/ Region Skåne "Förebygg sjukdom - framtidens möjlighet" vid Lunds Universitet. Mer information och video finns på länken http://www.med.lu.se/forskning/forskningens_dag/forskningens_dag_2009.
2. **Riesbeck K.** Ajour Dont 19: 216 (2010): "Streptokocker i nässpray kan lindra besvär hos öronbarn"
3. **Riesbeck K.** Sydsvenska Dagbladet 2011-04-09: fyra-sätt-att-tackla-en-antibiotikalos-framtid
4. Nyhetsbrev för massmedia, Region Skåne 2011-12-13: Schaar V och **Riesbeck K**: "De försöker överlista bakteriers samverkan".
5. **Riesbeck K.** Möt Labmedicin Skåne 2012-02-19: "Nedre och övre luftvägsinfektion".
6. **Riesbeck K.** Helsingborgs Dagblad 2013-01-28: kla-sig-varmt-basta-forsvar-mot-forkylning
7. **Riesbeck K.** Helsingborgs Dagblad 2013-09-28: munskydd-ar-forkastligt
8. **Riesbeck K.** Allmänna sjukhuset stiftelse för bekämpande av cancer 2013-03-20: "Går det att vaccinera mot magsäckscancer?"
9. **Riesbeck K.** Metro 2015-02-16: nej-det-ar-inte-riskfritt-att-kyssa-en-forkyld-person
10. **Riesbeck K.** Lunds Universitet maj 2016, pod-publicering om vaccin. <http://www.vetenskaphalsa.se/nytt-poddavsnitt-vaccinerna-som-forpassar-sjukdomar-till-medicinhistorien/>
11. **Riesbeck K.** *Moraxella catarrhalis* – en bakterie som har många strategier för överlevnad. BestPractice Lungmedicin, (2016)

12. **Riesbeck K.** Sydsvenska Dagbladet: om hosta. <https://www.sydsvenskan.se/2017-02-22/hall-koll-pa-hostan-det-kan-vara-kikhosta-flera-vuxna-i-skane-drabbade> (2017)
13. **Riesbeck K.** *Lunds Universitet*; Fokus Forsknings temanummer inför vetenskapsveckorna: "Blir världen bättre/Is the world becoming a better place".
<http://www.fokusforskning.lu.se/2017/03/03/spridningen-av-allvarliga-infektioner-okar/>
<http://www.researchmagazine.lu.se/2017/03/01/the-spread-of-severe-infectious-diseases-are-increasing/>
14. John Thegerström och **Riesbeck K.** *Haemophilus influenzae* och resistensutveckling. BestPractice Lungmedicin, (2018)
15. Oskar Thofte och **Riesbeck K.** Elongation Factor Tu – ett gåtfullt protein, BestPractice Lungmedicin, (2019)
16. **Riesbeck K.** (2020) <https://www.land.se/halsa/magsjuka-eller-vinterkraksjuka/>
17. **Riesbeck K.** (2020) <https://www.aftonbladet.se/family/a/1BvBmX/experten-sa-bor-ni-gora-med-tomten-i-pandemin>
18. **Riesbeck K.** (2021) https://www.vetenskaphalsa.se/fragor_svar_covidvaccin/
19. **Riesbeck K.** (2021) <https://www.vetenskaphalsa.se/vaccin-mot-covid-19-sa-funkar-de/>
20. **Riesbeck K. et al.** 2021. Digital föreläsning om vaccin I Region Skånes regi
21. LU: <https://www.lu.se/artikel/totalresistenta-bakterier-fran-krigets-ukraina-ar-extremt-sjukdomsframkallande?ref=pressrelease>
22. LU - English: <https://www.lunduniversity.lu.se/article/pandrug-resistant-bacteria-war-ukraine-are-extremely-pathogenic>
23. DN: <https://www.dn.se/varlden/totalresistenta-bakterier-i-krigets-ukraina/>
24. Science: <https://www.science.org/content/article/war-torn-ukraine-has-become-breeding-ground-lethal-drug-resistant-bacteria>
25. The Independent: <https://www.independent.co.uk/news/science/ukraine-war-drug-resistant-bacteria-amr-b2659843.html>
26. The Times, UK: <https://www.thetimes.com/article/drug-resistant-superbugs-antibiotics-ukraine-nhs-q7lnhtjmq>
27. Sveriges Radio: <https://www.sverigesradio.se/artikel/krig-och-havererad-var-d-kan-ge-livsfarliga-bakterier>
28. Vetenskapsrådet: <https://www.forskning.se/2024/12/09/totalresistenta-bakterier-fran-krigets-ukraina-ar-mycket-smittsamma/>
29. Polen: <https://www.medonet.pl/zdrowie/wiadomosci,superbakteria-wykryta-w-ukrainie--odporna-na-leki-i-bardziej-agresywna,artykul,75785148.html>
30. Spanien: https://www.elespanol.com/ciencia/salud/20241201/profesor-sueco-alerta-bacterias-superresistentes-llegan-guerra-ucrania-inmunes-tratamiento/904909591_0.html
31. EurekAlert: <https://www.eurekalert.org/news-releases/1066045>
32. Laboratory equipment: <https://www.laboratoryequipment.com/616378-Pandrug-resistant-Bacteria-from-the-War-in-Ukraine-are-Extremely-Pathogenic/>
33. Sydsvenska Dagbladet: <https://www.sydsvenskan.se/2024-12-15/multiresistent-bakterie-upptackt-i-skane-borde-du-vara-orolig/>
34. Göteborgs posten: <https://www.gp.se/nyheter/sverige/bakterier-i-krigets-ukraina-bade-resistenta-och-smittsamma.bbb5026c-49a5-4341-b668-19d07f677bc9>
35. Der Spiegel: publiceras i mars 2025.
36. USA Today, West coast: ännu ej publicerad (250206)
37. Läkemedelsvärlden: ännu ej publicerad (250206)